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Abstract 
 Protein therapeutics like insulin and glucagon-like peptide-1 analogues are currently used 
as injectable medications for the treatment of diabetes mellitus. An orally administered protein 
therapeutic is predicted to increase patient adherence to medication and bring a patient closer to 
metabolic norms through direct effects on hepatic glucose production.  The major problem facing 
oral delivery of protein therapeutics is gastrointestinal tract hydrolysis/proteolysis and the 
inability to passage the enterocyte.  Herein we report the potential use of vitamin B12 for the oral 
delivery of protein therapeutics.   
 We first investigated the ability of insulin to accommodate the attachment of B12 at the 
B1 vs. B29 amino acid position.  The insulinotropic profile of both conjugates was evaluated in 
streptozotocin induced diabetic rats. Oral administration of the conjugates produced significant 
drops in blood glucose levels, compared to an orally administered insulin control, but no 
significant difference was observed between conjugates.  We also report, for the first time, a dose 
dependent response of a B12-insulin conjugate. We then explored the implications of B12 
conjugation on the biological activity of the potent peptide glucagon-like peptide-1 (7-36) amide, 
with a K34R amino acid substitution.  Various in vitro bioassays utilizing human embryonic 
kidney cells and human pancreatic islets were conducted and indicated B12 has a minimally 
negative effect on GLP-1 biological activity.  Finally we modified the structure of B12 for future 
conjugation work.  The modification of the 5’hydroxyl group of the ribose unit of B12 to a 
carboxylic acid is predicted to benefit the field of B12 conjugation significantly with the ability to 
produce higher yielding and more stable B12 conjugates.   
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Chapter 1 General Introduction 
1.1 Diabetes Mellitus 
 Diabetes mellitus (DM) is a series of diseases characterized by the body’s inability to 
produce (type I, T1D) or properly use (type II, T2D) the hormone insulin, resulting in 
abnormally high blood glucose levels.1  T1D accounts for 5-10% of all newly diagnosed cases 
and is a result of the body’s immune system destroying pancreatic β cells,2, 3 which are the only 
cells in the body capable of producing insulin.  In addition to genetic factors, environmental 
conditions have also been described as risk factors for T1D.2, 4  There is no known prevention for 
T1D and it is usually diagnosed in people younger than 30.2  In T2D, there is an inability to 
produce enough insulin to meet the body’s insulin sensitivity level.  As the disease progresses, 
pancreatic β cell mass declines and the insulin deficiency increases.  The onset of T2D is usually 
later in life, although it has recently been diagnosed in children.1, 5, 6  T2D is much more prevalent 
then T1D, accounting for 90-95% of all new cases.  Research suggests physical inactivity and 
excess body weight increases your risk for T2D.7-11   
 According to a study conducted in 2011 by the Center for Disease Control and Prevention 
(CDC), 8.3% of the United States’ population is affected by DM.1  The number of DM cases is 
expected to increase significantly in the coming years, if current trends continue.1  DM is 
currently the third leading cause of death in the United States, just behind cancer and heart 
disease.1, 12  The high morbidity rate associated with DM has been attributed to the microvascular 
(retinopathy, nephropathy, and neuropathy) and macrovascular (cardiovascular disease) 
complications that result due to prolonged hyperglycemia.13  The annual diabetes-related 
spending in the United States is also expected to increase from $113 billion to $336 billion by 
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2034.14  The increasing prevalence and growing costs associated with DM has made it a major 
healthcare concern in the United States today.11, 12, 14  
1.2 Injectable Peptides and Proteins for the Treatment of DM 
 One of the primary goals for the treatment of DM is achieving and maintaining metabolic 
norms in regards to blood glucose levels (see Figure 1).15  Fluctuation in blood glucose levels 
often leads to serious health complications including retinopathy, nephropathy, and neuropathy, 
as previously mentioned.13  
 
Figure 1.  The primary treatment goal for DM is to maintain glycemic control (indicated as 
normal glucose level).  Glycemic control in a patient with diabetes can be challenging since the 
proper amount of insulin must be administered after meals.  Not injecting enough or injecting too 
much insulin will result in hyperglycemia or hypoglycemia, respectively.  While persistent 
hyperglycemia causes microvascular complications, hypoglycemia can cause diabetic coma or 
death.13, 16 
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 Patients with T1D require an exogenous source of insulin, often administered by 
subcutaneous injection, to maintain normal glycemic levels.  In T2D the body still produces 
insulin, but the cells are unable to use it efficiently.  The initial treatment for T2D is diet, 
exercise and oral anti-diabetic medications such as metformin,17 sulphonylureas,18 and 
thiazolidinedione (TZD)19 in an attempt to slow or reverse the disease.  These oral treatments 
lose efficacy over time as the disease progresses and a transition to injectable medications is then 
required.20, 21  Injectable insulin has been the primary medication for DM since its discovery in 
1922.15  Recent research has focused on the importance of incretin peptides like glucagon like 
peptide-1 (GLP-1) for the co-management of DM.22, 23 
 1.2.1 Insulin 
  1.2.1.1 History and Discovery 
 A number of important scientific observations led to the ultimate discovery of insulin in 
1922 by Canadian scientists Frederick Banting, Charles Best, John Macleod and Bertram 
Collip.24-26  In 1869, Paul Langerhans, a German medical student, observed a cluster of cells 
within the pancreatic tissues that did not have a reported function.  This cluster would later be 
named the ‘islets of Langerhans’, and include insulin secreting β cells.  Twenty years later, Oskar 
Minkowski and Joseph van Mering determined removing the pancreas of a dog resulted in 
diabetes, but ligating the duct through which pancreatic juices flow to the intestines only resulted 
in minor digestive problems, but not diabetes.  This suggested the pancreas had at least two 
functions and one of them involved the regulation of glucose.27  
 It was Dr. Frederick Banting that hypothesized that pancreatic digestive juice may be 
harmful to the pancreatic secretion produced by the islets of Langerhans.  Banting convinced 
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Professor John Macleod at the University of Toronto to fund his idea and he began work in 1921.  
As a surgeon, Banting was able to ligate the pancreatic ducts prior to extraction of the pancreas.  
His work led to the successful isolation of insulin.  The insulin extract was first tested in diabetic 
dogs with great success.28  The first attempt to inject the extract in humans, however, failed.  
With the help of biochemist Bertram Collip, the extract was further purified and used 
successfully in the treatment of a 14 year old diabetic patient in 1922.21, 28  The news of the 
successful treatment of diabetes with insulin rapidly spread and in 1923 Banting and Macleod 
won the Nobel Prize in Physiology or Medicine.  Banting decided to share his cash award with 
Best and Macleod shared his cash award with Collip.  
  1.2.1.2 Biosynthesis and Secretion of Insulin 
Insulin is produced in the pancreatic β cells of the islets of Langerhans.  The process 
involves multiple steps beginning with the prohormones ‘preproinsulin’ and ‘proinsulin’ (see 
Figure 2).29  Initially, insulin mRNA is translated into the single chain precursor preproinsulin, 
which contains a 24 amino acid (aa), hydrophobic signal peptide directing the chain to the rough 
endoplasmic reticulum (RER).28, 30, 31  Shortly after entering the RER, a signal peptidase removes 
the signal peptide, forming proinsulin.  
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Figure 2.  The subcellular organization of the insulin secretory pathway.   
 
 Proinsulin consists of a carboxyl-terminal A-chain, an amino-terminal B-chain, and a 
connecting peptide as the C-peptide (see Figure 3).31  In the RER lumen, proinsulin folds and 
three intrachain disulfide bonds form, linking residues 25-54 (B-chain) and residues 90-110 (A-
chain) and giving insulin its native structure.  The folding process is believed to be aided by a 
connecting segment at residue 55-89 (C-peptide), which is subsequently removed.31  Once 
folded, proinsulin is shuttled to the Golgi apparatus and is packaged into secretary vesicles.  In 
the vesicles, proinsulin is cleaved by the prohormone convertases 1/3 (PC1/3), 2 (PC 2) and 
carboxypeptidase E (CPE), finally generating active insulin and C-peptide.28, 32  PC1/3 and PC2 
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cleave between residue 32 and 33 at the C-peptide/B-chain junction and residue 65 and 66 at the 
C-peptide/A-chain.33  The removal of extra basic residues at the C-terminal end of the B-chain 
and C-terminal end of C-peptide occurs by CPE. 
Figure 3.  The post-translational modifications of preproinsulin, which results in active 
monomeric insulin and C-peptide. 
 
 Pancreatic β cells secrete insulin in a tightly regulated fashion to ensure glucose 
homeostasis.34  The mechanism for insulin secretion is a complex process involving the 
integration of intracellular and extracellular components and is still not completely understood 
(see Figure 4).  Nutrients, hormones, and neurotransmitters have all been shown to directly 
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stimulate insulin secretion.35, 36  Glucose is the most important physiological regulator of insulin 
secretion.  Calcium, adenosine triphosphate (ATP), cyclic adenosine monophosphate (cAMP) 
and phospholipid-derived molecules such as diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3) have all been identified as key intracellular components as well.35-37 
 Glucose induced insulin secretion (GIIS) occurs by three different pathways: the 
triggering pathway (KATP channel-dependent pathway), the metabolic amplifying pathway (KATP 
channel-independent pathway) and the neurohormonal amplifying pathway.38  During the 
triggering pathway, intracellular transported glucose is metabolized causing an increase in ATP 
concentration and subsequent closure of ATP sensitive K
+
 channels, which causes depolarization 
of the cell membrane and opens calcium channels, allowing calcium influx.  The rise in 
intracellular [Ca
2+
] triggers the fusion of insulin granules to the plasma membrane.  The 
mechanism of the metabolic amplifying pathway is less understood and believed to be more 
complex.  It is known that the triggering pathway most be operational and there must be an 
increase in intercellular [Ca
2+
] levels for the metabolic amplifying pathway to occur.34  In 
addition to glucose stimulation, hormonal inputs are important for normal regulation of insulin 
and occur by the neurohormonal amplifying pathway, which has recently been studied and is 
summarized in Figure 4.39 
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Figure 4.  Glucose induced insulin secretion (GSIS) is regulated by three pathways: triggering 
pathway, metabolic amplify pathway and neurohormonal amplify pathway.38  Gs: Gs α subunit, 
AC: adenyl cyclase.  
 
  1.2.1.3 Structure and Sequence of Bovine Insulin 
 In 1955, insulin became the first protein to be fully sequenced, winning Frederick Sanger 
the 1959 Nobel Prize for Chemistry.40  Insulin’s primary structure consists of two polypeptide 
chains, a 30 aa B-chain and a 21 aa A-chain (see Figure 5).41  The amino acids are referred to by 
the letter of the chain (A or B) and the position within the chain.  The aa sequence of insulin is 
highly conserved among different species, which allows the cross species use of insulin, for the 
most part.42  For research purposes the use of cross species insulin as a screen for biological 
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purpose is appropriate and well-studied.42  However, a transition to clinical use requires the use 
of human insulin to prevent immunological issues.43, 44 
 Bovine insulin, which was the source of insulin used for the work presented here, differs 
from human insulin by three aa: alanine for threonine at A8, valine for isoleucine at A10, and 
alanine for threonine at B30.43  The difference in aa does not alter the highly conversed 
secondary structure of the insulin.42  The insulin structure contains one intra-chain disulfide bond 
connecting residues 6 to 11 of the A-chain (A6-A11) and two inter-chain disulfide bonds linking 
the A- and B-chain (A7-B7 and A20-B19) (see Figure 5).41  The secondary structure of insulin 
includes a helical section between residues B9 and B19, as well as a N-terminal helix (A1-A8) 
linked to an antiparallel C-terminal helix (A12-20).45, 46   
 
Figure 5.  A representation of the primary structure of bovine insulin including the disulfide 
bonds formed between the A- and B-chains and the A-chain intrachain disulfide bond.  
 
 Insulin self-associates into dimers at micromolar concentrations, which is the 
concentration found in β cells during expression, suggesting dimers may be present in the 
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endoplasmic reticulum.29  The residues involved in dimerization are all located in the B-chain 
and have been identified as B8, B9, B12, B13, B16, B23-B29.45  Insulin further associates into 
hexamers at millimolar concentration in the presences of zinc ions.47 Insulin is stored as a 
hexamer in vacuoles of the β cells when blood glucose levels are low.  When blood glucose is 
elevated, the hexamers are released into the blood where they dissociate into dimers and 
monomers.  The dimer and hexamer formation is important for stabilization during storage.48  
The cellular actions of insulin are initiated by monomeric insulin binding to its plasma 
membrane receptor.29  
  1.2.1.4 The Insulin Receptor 
 The insulin receptor (CD220) is part of the receptor tyrosine kinase superfamily and is 
present on virtually all mammalian cells, although the concentration of CD220 varies across 
different cells.29  CD220 is a heterotetrameric glycoprotein consisting of two extracellular α- 
domains and two membrane spanning β-domains.  The domains are connected by disulfide bonds 
forming a β-α-α-β structure.  In simplest terms, insulin binds to an extracellular α-domain and 
causes phosphorylation of an intercellular β-domain.49   
 The crystal structure of the CD220 ectodomain was published in 2006 and provided 
valuable information about the structural organization of the receptor (summarized in Figure 6) 
and domains involved in insulin binding.50  The crystal structure of CD220-insulin complex has 
not yet been acquired, but the CD220 crystal structure combined with various experiments 
involving insulin analogues has provided a basis for a reasonable CD220-insulin binding 
model.49  The insulin residues involved in receptor binding include residues A1, A2, A3, A5, 
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A19, A21, B12, B16, and B23-26.51-53  It has also been suggested that residues A13 and B17 are 
involved in receptor binding.29  
Figure 6.  A carton representation of the domain organization within the homodimeric insulin 
receptor.  L1, L2: first and second leucine-rich-repeat domains, CR: cysteine-rich region, Fn0-1-2: 
fibronectin domains, Ins: Insulin insert domain, TM/JM: trans- and juxta-membrane regions, TK: 
tyrosine kinase domain and CT: C-terminal domain. 
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 1.2.2 Glucagon-Like Peptide-1 
 Glucagon-like-peptide-1 (GLP-1) is a gut hormone, produced in intestinal L cells, that 
increases the amount of insulin secreted from pancreatic β cells in response to ingested nutrients, 
also known as an incretin (see section 1.2.2.1).  Orally delivered glucose produces a dramatic 
increase in the secretion of insulin compared to injected glucose.54  This response to oral glucose 
is referred to as the incretin effect and accounts for 70% of the total postprandial insulin 
secretion.55   
 The role of GLP-1 in the postprandial homeostasis of glucose was established in the late 
1980s and early 1990s.56, 57  Recent preclinical and clinical research has established GLP-1’s role 
in increasing satiety,58-62 promoting modest weight loss,63 improving β cell function,64, 65 and 
preserving β cell mass by inducing proliferation,65, 66 which may help to slow or reverse the 
progression of T2D.66  The insulinotropic activity of GLP-1 is glucose dependent, making it an 
ideal treatment for hyperglycemia, since hypoglycemia is unlikely to occur as a result of 
treatment.67, 68   
  1.2.2.1 Discovery of the Incretin Effect 
 It was first speculated in the early 1900s that there was a component in the gut that was 
released after oral ingestion of nutrients, which caused insulin secretion.55, 69  Zunz and Labarre 
were able to extract an intestinal component that produced a lowering of glucose levels in dogs.70  
They introduced the term “incretin” to describe the extract.  Several other groups pursued the gut 
component with some reports of the presence of glucose lower abilities.54, 70, 71  However, Loew 
and colleagues reported the inability to lower blood glucose levels in dogs with the extract and 
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interest in the extract quickly declined.70  It was later determined that Loew’s experiments 
involved fasting animals, which would not respond to the glucose dependent GLP-1.70 
 Interest in the extract rekindled in 1960s with the development of a reliable 
radioimmunoassay for insulin, by Yalow and Berson.72  The ability to measure the circulating 
levels of insulin allowed researchers to determine the action of glucose alone could not account 
completely for the insulin secretion.  In 1969, Creutzfeldt defined the criteria for an incretin as 1) 
nutrients like carbohydrates must cause incretin secretion and 2) at physiological levels, elevated 
blood glucose levels must cause it to stimulate insulin secretion.70  The first incretin, glucose-
dependent insulinotropic polypeptide (GIP) was identified in the 1970s.  In the 1980s, with the 
help of complementary deoxyribonucleic acid (cDNA) cloning, GLP-1 was identified.70 
  1.2.2.2 Biosynthesis and Secretion 
 GLP-1 is produced in the intestinal L cells, which are located in the ileum and colon.73, 74  
As with insulin, the synthesis of GLP-1 involves a larger precursor, which is then 
posttranslationally modified to the functional form.  The process begins with the prohormones 
“preproglucagon” and “proglucagon”.  The preproglucagon has a signal peptide directing it to 
the secretory pathway, which is quickly removed to produce proglucagon.  Posttranslational 
cleavage of proglucagon is organ specific with PC2 producing glucagon in pancreatic α cells and 
PC1/3 producing GLP-1 in intestinal L cells.74
 
 
 GLP-1 was originally synthesized and tested as 36 and 37 aa peptides, GLP-1 (1-36) 
amide and GLP-1 (1-37), respectively.70  The sequences were based on a predicted 
posttranslational modification based on the understanding that PCs cleave a prohormone to the 
active hormone at a dibasic aa sequence.70  Therefore, the cleavage was assumed to occur 
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between the Lys and Arg resulting in a 37 or 36 aa peptide, depending on the presence or 
absence of the Gly residue at the C-terminus.  C-terminal amidation of peptide hormones is 
common and involves the oxidation of a C-terminal Gly, resulting in the conversion of a 
carboxyl to an amide on the preceding aa.75  The conversion to the amide does not occur 
completely, resulting in non-amidated and amidated peptide.75  Amidation of the GLP-1 
enhances the survival of GLP-1 in plasma. 75, 76 
 After early tests determined the GLP-1 (1-36) amide and (1-37) isoforms had no 
insulinotropic effects, reanalysis of the aa sequence determined His7 should be the N-terminal 
amino acid.70, 75  The reanalysis was based on alignment of other membranes of the glucagon 
superfamily of peptides.  Testing of GLP-1 (7-36) amide and GLP-1 (7-37) confirmed the 
truncated forms were indeed the insulinotropic forms of the peptide.70  The functions of the GLP-
1 isoforms GLP-1 (1-36) amide and (1-37) are still unknown.  There are two biologically active 
forms of GLP-1: GLP-1 (7-37) and GLP-1 (7-36) amide, and both are found in the circulation of 
humans.  GLP-1 (7-36) amide is the predominant form, accounting for typically 80% of 
circulating GLP-1. 75, 77 
 GLP-1 secretion is stimulated by ingested nutrients and occurs in a biphasic pattern.78  
Initially there is a rapid increase in the circulating GLP-1 level at 15-30 min after nutrient 
ingestion, followed by a second minor increase of GLP-1 at 90-120 min.78, 79  The second 
increase of GLP-1 is believed to be a result of nutrients interacting directly with the L cell to 
cause GLP-1 secretion.  Absence of L cells in the small intestines suggests the initial GLP-1 
secretion is mediated indirectly, rather than by direct L cell contact with nutrients.  Brubaker et 
al. proposed a mechanism involving the neuro/endocrine pathway for the indirect mediation of 
GLP-1 secretion.80  It was proposed that nutrients in the duodenum activate a proximal-distal 
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neuro/endocrine loop, which stimulates GLP-1 secretion from L cells in the ileum and colon.  
The incretin hormone GIP, the neurotransmitter acetylcholine and neuropeptide gastrin-releasing 
peptide (GRP) have all been identified as key regulators of GLP-1 secretion involved in the 
proximal-distal neuro/endocrine loop.80  
  1.2.2.3 Structure and Sequence of Human GLP-1 
 GLP-1 is a 3.3 kDa peptide containing 30 aa residues (see Figure 7).  The primary 
structure is highly conserved in mammalian species.70  The conservation of GLP-1 reflects the 
fact that basically the entire aa sequence is required for full biological activity.  Removal or 
addition of amino acids at the N-terminus of the GLP-1 (7-36) amide or GLP-1 (7-37) results in 
a dramatic loss of receptor binding and biological activity.70  Addition of an aa residue at the C-
terminal also results in a significant reduction in biological activity.70  
 
Figure 7.  The primary structure of human GLP-1 (7-36) amide.81  The C-terminal amidation has 
been shown to increase plasma stability.75  
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 Site specific mutation studies identified the following amino acids as important for 
receptor binding and activity: 1 (His), 4 (Gly), 6 (Phe), 7 (Thr), 9 ( Asp), 22 (Phe) and 23 (Ile).82, 
83  NMR studies of the structure of GLP-1 identified the N-terminus as a randam coil from 
residues 1-7, two helical segments at residues 7-14 and 18-29 and a linker region at 15-17 (see 
Figure 8).84 
Figure 8.  The secondary structure of GLP-1 (7-36) amide determined by solution NMR. Lys 26 
(indicated as ball and stick) has been identified as the best position for conjugation.85  Protein 
data bank ID: 1D0R. Modified using RCSB PDB protein workshop software 3.9. 
 
  1.2.2.4 The Glucagon-like Peptide Receptor 
 The therapeutic potential of GLP-1 receptor (GLP-1R) targeting for the treatment of T2D 
has been validated through extensive basic, clinical and translational research.63, 67, 68, 79, 86  GLP-1 
mediates its insulinotropic effects by binding to GLP-1Rs on pancreatic β cells.  The GLP-1R is 
a seven-transmembrane class B heterotrimeric G protein-coupled receptor (GPCR).  The B class 
is a subfamily of GPCR distinguishable by a large N-terminal extracellular domain (ECD), 
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which are typically 120 residues long and contain six highly conserved cysteine residues.87  The 
ECD is responsible for peptide recognition and selective binding.  GLP-1R’s ECD is composed 
of an N-terminal α-helix, two anti-parallel β strands, and a final lobe composed of two additional 
anti-parallel β sheets and a short α-helical region.88   
The X-ray crystal structure (2.1 Å resolution) of GLP-1 bound to the ECD of GLP-1R 
identified GLP-1 (7-36) amide as a continuous α helix from amino acid residues 13 to 33, with a 
kink around residue 22.76  Interaction between the ECD and GLP-1 were noted between residues 
24 and 33.  Specifically, the hydrophobic face of GLP-1’s α-helix interacts with ECD at residues 
24, 25, 28, 29, 32 and 33.76 
1.3 A Pursuit of a Noninvasive Peptide/Protein Treatment for Diabetes Mellitus  
 The oral delivery of peptides and protein is a major goal for therapeutics.89  Early work to 
develop an oral route focused primarily on a desire to increase patient adherence to medication 
and quality of life.90  Recent research has evolved to place new emphasis on the physiological 
importance of an orally administered peptide or protein,90, 91 with such delivery postulated to 
bring a patient closer to metabolic norms through direct effects on hepatic glucose production.89 
 
 
The major problem facing oral delivery of peptides and proteins is gastrointestinal tract (GIT) 
hydrolysis/proteolysis and the inability to passage the enterocyte.92 
 The initial barrier for oral delivery of peptide and proteins is the enzymatic barrier.89  
Pepsin is the major enzyme found in the stomach and is a key element in digestion.  In the 
intestines there are three major proteases responsible for further digestion: trypsin, chymotrypsin 
and carboxypeptidase.  Degradation of the peptide/protein by proteolysis will result in a reduced 
bioavailability.89  
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 If the peptide/protein makes it through the proteolytic barrier, the next major barrier is a 
physical barrier produced by the mucin lining of the intestines.  Mucus plays an important role in 
determining the absorption and bioavailability of orally administered drugs.93  The intestinal wall 
is the next barrier for drug delivery and is also a physical barrier.  Drug delivery is focused on 
the mucous layer of the intestinal wall, which is comprised of villi that extend out from the 
epithelial lining and are responsible for absorption of the majority of nutrients.94  Adsorption of 
nutrients from the intestine can occur by two major pathways: transcellular and paracellular (see 
Figure 9). 
 
Figure 9.  An illustration of the physical barriers and available pathways for oral drug delivery 
in the intestines.  
 
 The transcellular pathway involves passive or active diffusion through the intestinal 
epithelial cells, while the paracellular pathway takes place in the interstitial space between the 
epithelial cells.  In transcellular passive diffusion, small nutrients can cross through nonspecific 
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permeability pathways.  Larger nutrients, like vitamin B12, must use a receptor mediated uptake 
pathway to utilize the transcellular route.89  The paracellular route is regulated by epithelial tight 
junction proteins and is only open to small solutes, ions and water.95  The tight junctions are 
important for keeping the cells tightly bound to one another.  
 1.3.1 Strategies for Oral Delivery of Peptides and Proteins 
 Numerous strategies have been attempted to overcome the barriers associated with oral 
delivery of peptides/proteins.  The methods most commonly used include the use of enzyme 
inhibitors,93, 96-98 encapsulation,99, 100 chemical modification101 and/or absorption enhancers.102-104  
While there have been great strides towards the delivery of oral peptides/proteins because of 
these strategies, all of the methods have negative aspects that have kept them from reaching a 
clinical level.102  
 Early research focused on the use of enzyme inhibitors to reduce the rate of proteolytic 
degradation of orally delivered peptides/proteins.98  The potential for this technique was 
demonstrated by the use of a duck ovomucoid, which provided insulin 100% protection from 
trypsin and chymotrypsin.93  The major concern with the use of enzyme inhibitors is the potential 
side effects associated with continuous use including the potential for alteration to the body’s 
metabolism.102 
 Absorption enhancers work by altering the permeability of the cell membrane and include 
surfactants, chelating agents, zonular occludens toxin, and fatty acids.102  Detergents and 
surfactants disrupt the lipid bilayer of the cell membrane, enhancing the trancellular pathway.
94, 
95
  Chelating agents and zonular occludens toxin disrupts the integrity of the tight junctions 
enhancing the paracellular pathway.103, 104  A major drawback to the use of absorption enhancers 
20 
 
is that by altering the permeability of the cell membrane potential toxins and pathogens have 
access to the circulatory system.102  
 Various encapsulation techniques, including emulsions, liposomes, microsphere, and 
nanoparticles, have been attempted to protect peptides/protein.99, 101, 105 Nanoparticle based 
peptide and protein drugs have gained a lot of attention in recent years.  Nanoparticles are 
usually designed to deliver a large encapsulated load of peptide/protein to the intestines where a 
trigger (often pH based) releases the load for uptake at the intestinal wall.99, 106  The difficulties 
with the use of nanoparticles include the lack of specific control of drug release and the potential 
for buildup of non-degradable particles in tissues.99, 102 
 Chemical modification of peptides/protein includes amino substitution, to eliminate 
recognition sites of proteases or the attachment of various chemical moieties that are known to 
protect the peptide or protein from proteolysis.101, 106-109  One example of attachment of a chemical 
moiety is the addition of PEG, which has the ability to protect peptides and proteins from 
intestinal proteolysis as well as alter the interactions of the molecular with blood proteins, 
allowing for an increase in systemic circulation time.101, 106-109 
 1.4 Vitamin B12  
1.4.1 History   
 The early history of vitamin B12 (B12) belongs entirely to the field of medicine and the 
treatment of pernicious anemia.  Pernicious anemia was first described in 1824 and was an 
incurable and usually fatal disease.110  In 1920, Whipple discovered a diet of raw liver could 
regenerate the red blood cells of anemic dogs and in 1926, Minot and Murphy reported the same 
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findings in anemic patients.111  This discovery won all three the 1934 Nobel Prize in Physiology 
and Medicine.110 
 In 1948, B12 was isolated from the liver and determined to be the compound responsible 
for the improvement in pernicious anemia.  The isolation was performed by two independent 
groups, Folkers and coworkers at Merck Laboratories in the U.S. and Smith and Parker at Glaxo 
Laboratories in the U.K.112, 113  The X-ray crystal structure of B12 was obtained in 1955 by 
Dorothy Hodgkin.110, 114  This complex crystal structure of B12 won Hodgkin the 1964 Nobel 
Prize for Chemistry.  In 1972, Woodward and Eschenmoser reported the total synthesis of B12.
115 
It took over 100 scientists eleven years to complete this feat.116  Since these early years, 
thousands of papers have been published on the chemistry and biochemistry B12. 
1.4.2 Structure and Chemistry of Vitamin B12   
 B12, or cobalamin, is the most structurally complex cofactor existing in nature.
116  B12 is a 
member of a family of cob(III)alamin species all of which are comprised of a cobalt (III) ion 
equatorially coordinated to four pyrrolic nitrogens of a corrin ring (see Figure 10).117  The corrin 
ring is similar to the more commonly known porphyrin structure but with a greater degree of 
saturation and increased sp
3
 carbons, which confers greater flexibility.117  In addition, there is 
greater asymmetry to the corrin ring compared to a porphyrin, due to the fusion of the A and D 
rings resulting in a 15-carbon ring structure over the porphyrin 16-carbon structure.117  
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Figure 10.  Structure of B12 with a variable R group shown to the left.  Three of the more 
common forms of B12 (cyanocobalman, methylcobalamin and adenosylcobalamin) are shown to 
the right.  
 
 In humans, the cobalt atom is further bound to a 5,6-dimethylbenzimidazole (DMB) base 
at the α-axial position.117  The identity of the base varies in different species.117  DMB is 
connected to the D-ring of the corrin ring by a ribose-phosphate-amide bond linkage formed 
through the f amide side chain.  The functional group attached at the upper β position of the 
cobalt ion, depicted as R in Figure 10, is variable depending on the type of cob(III)alamin 
species.  The most common cob(III)alamin used in research and nutriceuticals is cyanocobalamin 
(see Figure 10, R = CN, CNCbl).118  CNCbl is not the biological active form of cob(III)alamin 
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but is readily converted to the biologically active forms, methylcobalamin (R= CH3, MeCbl) and 
adensylcobalamin (R= 5’-deoxyadenosyl, AdoCbl) in the human body.119 
The use of B12 as a cofactor is a result of the ability of the cobalt atom to change 
oxidations states.116  In AdoCbl, the cobalt atom is converted from Co
3+
 to Co
2+
 (cob(II)alamin) 
by homolytic cleavage of the Co-C bond.  In MeCbl, heterolytic cleave of the Co-C bond results 
in a Co
+
 (cob(I)alamin) species.116  
1.4.3 Physiological Roles of B12  
 B12 plays an important role in the normal functioning of the brain and nervous system 
(myelin production), the formation of blood (tetrahydrofolate production), DNA synthesis 
(ribonucleotides reductase (RNR) conversion of ribonucleotides to deoxyribonucleotides), and 
fatty acid synthesis and energy production.120-122  Many of B12 functions can be replaced by folic 
acid (vitamin B9) but two enzymes absolutely require B12 as a cofactor, methylmalonyl 
coenzyme A mutase and methionine synthase.122   
 Cytosolic methionine synthase is a MeCbl-dependent methyl transferase responsible for 
the formation of methionine by methylation of homocysteine.123  The process is a catalytic cycle 
involving two methyl transfer half-reactions, outlined in Figure 11.  The cobalt-bound methyl 
group of MeCbl is transferred to homocysteine, forming methionine and an enzyme-bound 
cob(I)alamin.124  This highly nucleophilic cob(I)alamin then acquires the methyl group of N
5
-
methyltetrahydrofolate, forming tetrahydrofolate and MeCbl.123  Tetrahydrofolate is essential for 
the production of purines and pyrimidines in DNA synthesis.123   
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Figure 11.  Outline of methionine synthase (Enz) catalytic cycle, which involves two methyl 
transfer half-reactions: homocysteine to methionine and N
5
-methyltetrahydrofolate to 
tetrahydrofolate.  
 
 Methylmalonyl Coenzyme A mutase is an AdoCbl-dependent enzyme, which catalyzes 
the rearrangement of methylmalony-CoA to succinyl-CoA.124  This rearrangement occurs by the 
exchange of a hydrogen atom from the methyl group with the carbonyl-CoA group on the 
adjacent carbon.  This conversion from methylmalonyl-CoA to succinyl-CoA is an important 
step in the degradation of branched-chain amino acids, and odd-chain fatty acids.124  
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1.4.4 The Dietary Uptake Pathway Overview  
 B12 is vital for the survival of all living organisms and is only synthesized naturally by 
bacteria, so mammals must acquire the vitamin through their diet.123  As a result, the body uses a 
complex uptake mechanism involving three soluble transport proteins (haptocorrin (HC), 
intrinsic factor (IF) and transcobalamin II (TCII)) to ensure successful isolation of B12.
120  The 
uptake pathway also utilizes four receptors (cubilin, amnionless, megalin, and TCblR/CD320), 
which only recognize a B12 transport protein when bound to B12.  Any disruption in the uptake 
pathway is known to result in a B12 deficiency.
120  In the most basic terms, the uptake pathway 
begins with the protection of B12 from the acidic environment of the stomach by HC, followed 
by the receptor mediated uptake of IF bound to B12 in the intestines and B12 delivery to the cell 
by TCII (see Figure 12). 
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Figure 12.  An overview of the B12 uptake pathway as outlined by a recent 2012 review.
120  The 
transfer of B12 from IF to TCII is currently being debated as discussed in section 1.4.7 and shown 
in Figure 15.  Image is reproduced from reference 120 with permission of Nature Publishing 
Group. MRP1: multidrug resistance protein 1. 
 
 A number of important publications have been received in recent years providing a 
clearer picture of the exact mechanism of B12 transport.
125-132  There are still areas of the pathway 
that are not completely understood and some areas of the pathway that are controversial in the 
B12 field.  What follows is a review of the current understanding of the B12 uptake pathway:  
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1.4.5 Haptocorrin  
 HC is a 45.6 kDa glycoprotein primarily secreted in human saliva at concentration of 50 
nM.133  The predominant function of HC is the transport of B12 through the acidic environment of 
the stomach and into the duodenum.134  In the duodenum, an increase in pH causes the release of 
B12 and pancreatic proteases cleave the HC.  The release and break down of HC results in the 
transfer of ~80% of bound B12 to IF.
135 
 In the blood plasma, HC is believed to be responsible for the removal of partially 
synthesized or degraded B12.
136  HC is the only known B12 transport protein capable of binding 
corrinoids, which are a large group of compounds containing the corrin ring with coordinated 
cobalt.  Approximately 40% of plasma corrinoids are a B12 analogue unable to serve as a 
cofactor.  Due to HC presence in breast milk, tears and salvia, it was suggested that haptocorrin 
may also have antibacterial functions118 but a recent paper contradicts this hypothesis.128 
 HC is the least understood of the B12 transport protein.  It was recently established that 
HC is not present in all species, which was an extremely important finding as a number of B12 
studies are conducted in nonhuman subjects.127  No crystal structure has been reported, but the 
structure of HC is predicted to be very similar to IF (see section 1.4.5).137  The recombinant 
expression of human haptocorrin was recently reported in human embryonic kidney (HEK) 
cells.138  This successful expression will allow researchers the ability to produce and more 
extensively study HC in the coming years. 
1.4.6 Intrinsic Factor  
 The second B12 transport protein in the series, IF is a highly glycosylated protein secreted 
in the parietal cells and is crucial for B12 transport across the intestinal wall.
125  IF binds B12 in 
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the large intestines after proteases degrade HC and the pancreas secretes a bicarbonate solution 
that neutralizes the acidic stomach content.138  IF can only bind B12 and is reported to be the first 
filter in the B12 uptake pathway.
122  The IF-B12 complex crosses the intestinal wall in the ileum by 
receptor mediated endocytosis via the cubam receptor complex.125, 139 The cubam receptor 
complex consists of two receptors cubilin and amnionless (see section 1.4.6).139  Once in the 
lysosome, IF is degraded by cathepsin L and B12 is released.
140,120  B12 is transported across the 
lysosomal membrane with the aid of the lipocalin membrane receptor like protein LMBD1.130  
Once B12 is in the cytoplasm, there is debate as to how B12 leaves the cell, which will be 
discussed in section 1.4.7. 
 The crystal structure of IF bound to B12, at 2.6-Å resolution was published in 2007, 
providing a picture of how the 60 kDa protein binds B12 (see Figure 13).
129  The structure of IF is 
very similar to the structure of TCII, which was reported in 2006 and is discussed in section 
1.4.7.132  IF contains 399 aa residues plus 15% carbohydrate and is comprised of two domains, a 
270 residues α domain and a 110 residue β domain. 129  As the names suggest, the α domain is an 
intertwined α6/α6 helical barrel and the β domain is a cluster of β strands (see Figure 13).  The 
B12 binding site is located between the α and β domains and about 19% of the B12 is solvent 
exposed when bound by IF.129  There are five residues from the α domain (His73, Tyr115, 
Asp153, Asp204, and Gln252) and four residues from the β domain (Ser347, Val352, Phe370, 
and Leu377) that form direct hydrogen bonds with B12.
129  The B12 DMB group is maintained in 
a hydrophobic environment made up of a β-hairpin molded by residues 343-352 of the β 
domain.129 
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Figure 13.  Ribbon diagram of IF-B12 complex with the B12 shown in ball and stick. Used with 
permission of National Academy of Science from reference 129. 
 
1.4.7 Cubilin and Amnionless 
 The transport of B12 across the intestinal wall occurs in the terminal ileum with the aid of 
IF and the cubam receptor complex.125, 139, 141 The cubam receptor complex consists of two co-
expressed receptors in the apical membrane of the ileum: cubilin and amnionless.139  The cubilin 
receptor is a 460 kDa glycoprotein and is comprised of eight epidermal growth factor (EGF)-like 
repeats followed by 27 complement CUB (components C1r/C1s, the sea urchin protein Uegf, and 
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bone morphogenic protein-1) domains.125  The CUB domains are the ligand binding region and 
accounts for 85% of the receptor.125  Cubilin has domains for the binding of a number of ligands 
including vitamins, lipids and hormones.142  
 The IF-B12 complex binds to the CUB 5-8 domains and the interaction is calcium 
dependent.125, 143  B12 and IF are only recognized by the CUB domain as a complex.
142  A recent 
crystal structure of the CUB 5-8 domains bound to IF-B12 identified both α and β domains of IF 
interacting with the CUB domains (see Figure 14).125  Specifically residues 25-299 of the IF α 
domain interact directly with CUB 6 domain and residues 308-417 of IF β domain interact 
directly with the CUB 8 domain.
125  The internalization of CUB bound to IF-B12 is facilitated by 
amnionless, a 48 kDa transmembrane protein.139  Amnionless contains internalization signals 
within its cytosolic domain known to induce endocytosis by clathrin-coated buds.125  
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Figure 14.  The structure of CUB 5-8 (left, blue) interacting with IF bound to B12 (right, green 
and pink).  The interaction is calcium (red sphere) dependent.  The image is reproduced from 
reference 125 with permission from Nature Publishing Group. 
 
1.4.8 Transcobalamin  
 TCII is the primary B12 transporter in the blood serum and is responsible for the delivery 
of B12 to the cells by facilitating binding of B12 to the TCblR/CD320 receptor.
120  TCII is the only 
nonglycosylated B12 transport protein, known to date and is believed to be secreted from the 
vascular endothelium.144  When and where TCII binds B12 is still debated.
126, 145  In the early 
2000s, Alpers and Seetharam proposed the transfer from IF to TCII occurs within the enterocyte 
(see Figure 15a).145, 146 Just recently, research has demonstrated the ability of B12, with the aid of 
MRP1, to leave the enterocyte free of a transport protein (see Figure 15b).126  Further work needs 
to be done to determine when TCII binds B12.  What is known for sure is TCII is bound to B12 in 
the blood serum and transports B12 to the TCblR/CD320 or megalin receptor (discussed in 
section 1.4.9).137 
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Figure 15.  There are currently two theories involving the export of B12. a) Seetharam et al. 
present B12 bound to TCII in the cell while more recently b) Nexo et al. have established an 
alternative export system involving MRP1. Images used from references 146 (a) and 120 (b) 
with permission from Cambridge University Press and Nature Publishing Group, respectively.  
 
 TCII was the first transport protein crystallized and the structure revealed a number of 
important details about points of modification on B12 including the presence of hydrogen bond 
formation between various residues in TCII and B12’s phosphate moiety and side chains of the 
corrin ring.132  The crystal structure also showed that TCII does not completely encompass B12 
upon binding, and leaves an exposed section of the vitamin accessible to solvent.  The 1.4 nm 
solvent accessible pocket of B12 bound to TCII shows the phosphate and ribose hydroxyl groups 
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are left protruding into the solvent, but only the 5’-hydroxyl of the ribose group is open to the 
environment enough that it can easily accommodate the conjugation of large molecules (see 
Figure 16).132   
 
 
Figure 16.  A representation of the TCII-B12 complex.  The TCII α-domain is shown on the 
bottom (red) with the β-domain on top (blue).  The B12 molecule is shown in ball and stick and 
found sandwiched between the two domains (orange).  Reprinted from reference 132 with 
permission of National Academy of Science.  
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1.4.9 Megalin and TCblR/CD320 
 The TCII-B12 complex is recognized by two cell-surface TCII receptors: TCblR/CD320 
and megalin.  The renal filtration and reuptake of B12 occurs in the kidney with the aid of TCII 
and the receptor megalin.142, 147  Megalin is a 600 kDa LDL-receptor family protein.148  The TCII-
B12 complex binds to megalin with high affinity and internalizes the complex, preventing loss of 
B12.
149   
 In the bloodstream, TCII transports B12 to the cell, where the TCII-B12 complex is 
recognized by a newly identified receptor, TCblR/CD320.150  TCblR/CD320 is a 58 kDa 
transmembrane protein that belongs to the low density lipoprotein (LDL) receptor family.  
TCblR/CD320 is present on the cell surface of virtually all tissue and a soluble form of the 
receptor has recently been identified in the bloodstream.151  The expression of the TCblR/CD320 
receptor has been linked to the proliferative and differentiation status of the cell.  The levels of 
TCblR/CD320 expression increase when cells are dividing, which relates to the fact that B12 is 
essential for DNA synthesis.123  Endocytosis of the TCII-B12 complex results in the degradation 
of TCII in the lysosome and the release of B12.  Once the B12 is released it can be stored in the 
cell, used as a cofactor or leave the cell.120  
 In contrast to TCII, haptocorrin seems to have a less important role in B12 delivery to 
cells, although haptocorrin that lacks terminal sialic acid is known to be rapidly cleared by the 
asialoglycoprotein receptor in the liver.138
, 152  The role of this receptor is believed to be involved 
in degradation of HC.  A receptor for sialylated HC has not been identified.138 
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1.5 Using the B12 Pathway for Drug Delivery 
 The use of B12 for drug delivery is focused in two main areas of research: targeted 
delivery of therapeutic and imaging agents and increased oral bioavailability of peptides and 
proteins.  B12 has been utilized for the delivery of imaging agents and therapeutic drugs for the 
treatment and diagnosis of cancer, due to the increased need for B12 in rapidly dividing cells.
153  
The increase in bioavailability of peptides and proteins is based on the potential the B12 uptake 
pathway has for overcoming the major barriers to oral delivery of peptides and proteins.154  The 
following section will be a review of the field of B12 drug delivery.   
1.5.1 Targeted delivery 
 Upon delivery to the blood stream, a B12 conjugate will typically be acquired by TCII, as 
previously discussed in section 1.4.5.120  In cancer therapy/imaging, the hypothesis for B12 based 
targeted delivery has historically been that increased TCblR/CD320 expression (as much as 3- to 
26- fold in certain patients)155 in a variety of cancers such as testis, breast, ovarian, thyroid, 
uterine, and brain cancer would provide sufficient selectivity over healthy cells.155  The increase 
in TCblR/CD320 expression in cancer cells has led to the production of both small organic and 
inorganic B12 conjugates with various applications in medicinal chemistry, which will be briefly 
discussed in this section and can be found in Table 1. 
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Table 1. B12-small molecule conjugates. 
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1.5.1.1 The Use of B12 for Imaging 
 Early investigators demonstrated that cobalt radionuclides (
57
Co, 
58
Co, 
60
Co) could be 
used to label B12 for imaging.
144, 156  The half-life of the radionuclide, however, required the 
dosage for humans to be too small for successful external images to be taken 
 
and the radioactive 
compounds were shown to accumulate in the liver, pancreas, and kidneys, leading to organ 
damage.157  In an attempt to overcome these issues, a number of additional radionuclides 
including 
111
In (2.8 days; 0.245 MeV-γ),157 
131
I (8 hrs; 364 keV-γ, 606 keV-β)158 and 
99m
Tc (6.02 
hrs; 140 keV-γ)159 have been conjugated to B12 for labeling purposes.  Unfortunately, these 
experiments still resulted in undesired organ accumulation, limiting the amount of drug delivered 
to cancerous cells and demonstrating high background uptake in healthy cells.157, 159, 160 
 Several fluorescent B12 imaging agents have also been synthesized.
161, 161-163  The first 
reported fluorescent B12 analogues utilized the β-axial position of the Co (III) ion for conjugation 
of the fluorophores (Fluorescein, napthofluorescein and Oregon Green), but low Co-C bond 
dissociation energy (~37 kcal/mol) caused the molecules to suffer from photochemical 
instability.164  A shift in conjugation sites to 5’-hydroxyl group of the ribose moiety162 and the 
addition of a rigid linker provided more stable B12 fluorescent moiety with an increase in 
fluorescent lifetime.163  An increase in the overall fluorescence quantum yield was observed with 
the use of a rigid linker over a flexible linker because the rigid linker orients the fluorophore 
away from the corrin ring of B12, minimizing through space intramolecular interactions.
163  The 
fluorescent agents are expected to be suitable as tumor markers to aid surgeons during surgery to 
remove the tumors, but no data supporting this claim has been published to date.163  The imaging 
agents will most likely suffer from nonselective TCII uptake in vivo. 
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 In an attempt to overcome background uptake, HC has more recently been targeted since 
receptors for haptocorrin are also overexpressed in a number of cancer lines.165, 166  To target HC 
over TCII, Alberto et al. disrupted the interactions between B12 and TCII by utilizing the b 
propionamide site after modification to the b monocarboxylic acid. 167  This is a considerable 
breakthrough for B12 based cancer therapeutics since it demonstrates one of the often stated 
problems of using B12 systems, namely non-specific cell uptake, can be addressed, at least 
towards cancer cell lines with de novo HC expression. 
1.5.1.2 Vitamin B12 Therapeutics 
 Nitrosylcobalamin (NOCbl) is a B12 derivative with nitric oxide (NO), a molecule known 
to induce apoptosis, as the β-axial ligand.168  Once in the cell, the NO detaches from B12 and has 
the potential to causes direct damage to DNA and inhibits cellular metabolism, leading to 
necrosis and apoptosis.169  In 2002, Bauer et al. analyzed 22 human tumor cell lines and two non-
tumor cell lines and concluded NOCbl had a greater selectivity for tumor cells and the tumor 
cells were more sensitive to the NOCbl.169  The NOCbl was determined to inhibit tumor growth 
in vitro and in vivo by activation of the extrinsic apoptotic pathway.168, 170 
Colchicine is a cytotoxic agent, which disrupts mitosis by binding to tubulin and 
inhibiting microtubule polymerization.171  The use of colchicine suffers from a lack of selectivity 
for cancer cell among a field of healthy cells, resulting in undesired side effects.171  In 2004, 
Grissom et al. employed B12 to deliver colchicine specifically to cancerous cells.
171  Using an 
acid labile hydrazone linker, colchicine was attached to the β axial ligand of B12.  The linker 
allowed for a pH-dependent release of colchicine in acidic conditions.171 Once taken into the cell 
via the B12 receptors, colchicine was released to interact with microtubules but showed a ten-fold 
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decrease in toxicity.171  In vivo experimentation demonstrating selectivity for cancer cells was 
not performed. 
 In 2009, Siega et al. determined it was possible to deliver Gd
3+
 to cancer cells by 
conjugation to B12.
172  By using the metal chelating agent DTPA, a B12–Gd
3+
 conjugate was 
constructed.  The Gd
3+
 moiety conjugated to the 5’-hydroxyl group of the ribose moiety of the 
B12 did not affect the binding of the B12 transport proteins.
172  Viability tests on human 
myelogenous leukaemia K562 cells incubated with the conjugate showed a significant decrease 
in cell viability compared to those incubated with the B12 parent compound and/or the Gd
3+
 ion 
alone.172  Given that this system utilized conjugation at the 5’-hydroxyl group of the ribose 
moiety, allowing TCII recognition, it can be postulated that this system, if tested in vivo, will 
give poor tumor specificity as well. 
 B12 can act as a ligand for cisplatin by formation of a cyanide-bridged species between 
the β-axial ligand of B12 and Pt.
173  B12–cisplatin conjugate retain a labile chloride ligand that can 
be exchanged with ligands such as guanine, allowing the conjugate to behave in a similar way to 
cisplatin.173  In 2008, Alberto et al. synthesized a number of prodrugs around the {B12-CN-Pt-R} 
moiety.174  Using an in vitro adenosylation assay from Salmonella enteric, the group was able to 
show that Co (III) was reduced to Co (II) and the Pt (II) complex was released.174  In 2011, the 
preliminary in vitro cytotoxicity of the {B12-CN-Pt-R} conjugate suggested a lower activity (IC50 
between 8 and 88 M) than for cisplatin alone.175  It is hypothesized that the limited B12 uptake 
capacity is most likely to blame.175  Studies on the effects of the uptake capacity on concentration 
are underway.175 
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 1.5.2 Oral Delivery of Peptides and Proteins 
 The investigation of B12 for the oral delivery of peptides and proteins began in the early 
1990s with the work of Russell-Jones.176, 177  In an attempt to establish a route of oral delivery for 
peptide and proteins, in general, Russell-Jones and co-workers conjugated B12 to a wide range of 
peptides and proteins between 1994 and 1999.176-178  The initial conjugate involved the 
attachment of luteinizing hormone releasing hormone antagonists (ANTIDE) to the B12 e 
carboxylic acid derivative.176  Exploration of the spacer units established the ability to attach two 
biological active molecules.  B12 was also determined to increase solubility of the protein.
155
  
Later the same year, work with granulocyte-colony stimulating factor (G-CSF) and 
erythropoietin (EPO) established the ability of B12 to deliver a biological active protein orally in 
an IF-dependent fashion in vitro and in vivo.177 
A number of issues with the B12 uptake pathway were determined with these early studies 
including the reduction of biological activity of the peptides or proteins, although sometime only 
slight.176  It was also determined the B12 uptake pathway had a limited uptake capacity (~1 nM 
per dose in humans) and so the system was restricted to highly active compounds.92  It was also 
stated that the system had no way of protecting the protein from proteolysis.92 
1.6 Points of Modification on B12 
Knowledge of the binding between B12 and its various transport proteins is critical if a 
B12 conjugate is to be successfully translated from bench to bedside.  In the last five years there 
has been an explosion of critical structural data related to the B12 uptake pathway with the 
publication of the IF,129 TCII132  and cubilin(5-8)-IF-B12 structures.
125  Researchers have a better 
understanding of how B12 interacts with its transport proteins, and how these transport proteins 
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interact with their receptors.  The implications this can have on drug delivery and sites of 
potential conjugation can then be better detailed, rationalized and hence optimized. 
The B12 and the molecule of interest can be: (1) coupled directly together, (2) held apart 
by ‘spacer’ units to produce distance between the B12 and drug or (3) carriers can be conjugated 
to B12 with the desired drug contained, unconjugated, within this carrier.  Several functional 
groups are readily available for modification on B12 including propionamides, ethylamides, 
hydroxyl groups, the cobalt (III) ion and a phosphate moiety.153  Only a few modifications are 
capable of maintaining the recognition of all three transport proteins needed to utilize the full B12 
uptake pathway effectively in an oral manner.137 
The size of the drug is important when considering the location for conjugation as well as 
the transport proteins being utilized since all three transport proteins are not created equally.  
Conjugation of drugs resulting in the recognition of all three transport proteins has been 
successful with B12 at three major sites: (1) to the peripheral corrin ring e propionamide
176; (2) to 
the 5’-hydroxy of the ribose 163; and (3) to the cobalt metal (see Figure 17).170
,
 179  
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Figure 17.  Conjugation can occur at any of the functional groups (indicated in shaded shapes) 
without loss of binding by the three uptake proteins.  
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1.7 Summary  
 An orally administered peptide/protein medication is important for increasing patient 
adherence to therapy as well as the physiological importance of mimicking the natural pathway 
of the peptide/protein.90  The uptake pathway of B12 makes for an excellent candidate for the oral 
delivery of molecules because it has the potential to overcome the major problems associated 
with oral delivery.  Before the full potential of the B12 uptake pathway can be realized, however, 
concerns about the pathway that have been brought to light in recent years, including the limited 
uptake capacity (~1.5-2.0 μg per dose in humans), need to be addressed.   
 The work presented here is based on the hypothesis that the B12 uptake pathway can be 
used to orally deliver active peptides and proteins.  To address this hypothesis, three important 
goals will be set (1) Gaining a better understanding of the previously designed B12-insulin 
conjugation system through the reexamination of the reaction conditions, alternative conjugation 
sites on insulin and modification of the B12 structure (2) Understanding the impact B12 
conjugation and the B12 uptake pathway has on peptide/protein function (3) Appreciate the 
limitation of the B12 uptake pathway and explore peptides suitable for B12 delivery. 
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Chapter 2 Investigating the B12 Uptake Pathway for the Oral Delivery of Insulin 
2.1 Introduction  
 The oral delivery of insulin at clinically significant and controllable levels is a major goal 
in the treatment of DM.1, 2  The removal of insulin injections is predicted to increase patient 
adherence to insulin therapy and increase patient’s quality of life.2, 3  Side effects of current 
insulin therapy include weight gain and hypoglycaemia, which have been correlated with the 
over-insulization of the periphery due to subcutaneous injections.4 
 Insulin is naturally secreted from pancreatic β cells directly into the portal vein and is 
then shuttled to the liver.4  During first pass through the liver, up to 70% of secreted insulin is 
extracted by insulin receptors located on the liver.5-7  The insulin extraction by the liver results in 
a higher concentration of insulin in the portal vein compared to the systemic circulation.4  
Subcutaneous injections bypass this first pass through the liver and result in an unnaturally 
higher concentration of insulin in the systemic circulation than in the portal vein.  The oral route 
of administration is postulated to mimic the natural route of insulin secretion with absorption 
from the GIT into the portal vein.4 
 The major problems facing oral delivery of peptides/proteins are hydrolysis/proteolysis in 
the GIT and an inefficient uptake mechanism for large peptides or proteins from the GIT (see 
section 1.3 for a more detailed discussion).8  We are interested in the use of the B12 dietary 
uptake pathway to address these hurdles to oral delivery. 
 The B12 dietary uptake pathway (discussed in detail in sections 1.4.4-1.4.9) utilizes a 
series of transport proteins and receptor to protect and shuttle the B12 from the mouth, across the 
intestines, and to the cell where it is utilized as a cofactor (see Figure 18).  For the oral delivery 
of peptides and proteins, we are primarily interested in the two transport proteins, HC and IF, 
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and the intestinal IF dependent cubam complex.  HC is important for the protection of B12 in the 
mouth/stomach and facilitates the transport of B12 to the intestines, where the second transport 
protein IF transports the B12 across the intestinal wall with the aid of the cubam complex (see 
section 1.4.7).9 
 
 
Figure 18.  A basic representation of the B12 dietary uptake pathway.  
 
Previously, Petrus et al. reported on the development and characterization of an orally 
active B12-insulin conjugate with hypoglycemic properties in the streptozotocin (STZ)-induced 
diabetic rat model.10  The oral administration of the B12-insulin conjugate resulted in a 4.7 fold 
greater decrease in blood glucose levels compared to orally administrated insulin in the STZ rat 
model.  It was determined that the B12-insulin’s glucose lowering ability was a result of the use 
of the B12 uptake pathway.  This determination was based on experimentation with co-
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administration of excess B12 and the conjugate, which resulted in a loss of glucose lowering 
ability.10  
Results from the initial work with B12-insulin,
10 stimulated further study into the 
implications of the B12 conjugation on insulin’s ability to bind to its receptor (CD220)
 
using 
immune-electron microscopy and molecular dynamics simulation.11  What is clear from the 
results obtained to date is that (i) B12 can deliver insulin to rat blood serum at levels significantly 
greater than the same administered concentration of ‘free’ insulin, and (ii) The B12-insulin 
conjugate can still dock to CD220, insulin receptor and thus trigger glucose uptake, even when 
bound to TCII. 
The use of the B12 pathway to deliver a clinically relevant bolus of insulin, or fast- acting 
insulin usually given with a meal,12 is not possible however, given both the limited uptake 
capacity (1.5-2.0 μg per dose)13 of the pathway and the relatively slow uptake time for serum 
delivery (~ several hours).8  The possibility of developing an oral, long acting basal therapy is 
more feasible, where a low level of long acting insulin is required and an initial uptake delay is 
not critical.12 
The earlier results with insulin10, 11 have been highly encouraging and we have become 
focused on investigating and improving in vivo residency of B12-insulin conjugates.  Before such 
an area can be fully explored however, knowledge of (i) the effects of B12 conjugation on the two 
main sites suitable for such on insulin (vide infra) and (ii) dose-response of B12-insulin 
conjugates needed to be addressed.  These important factors are discussed in this report. 
Insulin has two primary sites available for conjugation (the N
α
-amino group of 
phenylalanine B1 (PheB1) and the N
ε
-amino group of lysine B29 (LysB29)), which allow 
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biological function to be maintained (see Figure 19).14  It is not completely understood which 
position is more suitable for modification.15, 16  Significant differences between both positions 
upon B12 conjugation would be of great importance given the limited B12 uptake capacity and the 
need therefore to optimize such a conjugate.  
Figure 19.  The three amine groups available for conjugation on the bovine insulin structure are 
indicated.  Conjugation at the GlyA1 has previously been shown to eliminate biological activity, 
therefore only the PheB1 and LysB29 are available for conjugation.  
 
The original conjugate utilized the LysB29 position for B12 attachment based on the 
understanding that this amino acid is involved in the dimerization of insulin.16-18  Insulin is more 
stable as a hexamer, but the monomer is the only biological active form.17  Therefore, the 
suppression of dimerization and subsequent hexamerization would result in faster absorption of 
the conjugate.17  It has been reported that conjugation at the LysB29 position results in a 
reduction in biological activity due to the close proximity to the insulin receptor binding site.15  
Therefore, moving B12 further away from the binding site could result in an increase in biological 
activity. 
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We describe herein the synthesis, characterization, and purification of a new B12-insulin 
conjugate (1), which is attached at insulin PheB1 (Figure 19).  The use of PheB1 for attachment 
of B12 is also predicted to eliminate self-association of the insulin molecule because PheB1 is 
involved in insulin hexamerization.15  We hypothesize that this new conjugate may result in an 
increase in insulin’s biological activity, while maintaining the B12 uptake capabilities due to the 
position of B12 attachment in relation to the insulin receptor binding region.  The synthetic route 
of the previously investigated B12-insulin (B12 bound to insulin LysB29, 2)
10 was updated to 
increase yield and mimic as close as possible the synthetic route for the new B12-insulin (B12 
bound to insulin PheB1, 1). 
Both 1 and 2 were coupled at the B12-ribose hydroxyl group through a carbamate linker.  
Insulinotropic properties of 1 and 2 were evaluated in vivo in STZ induced diabetic rats.  
Molecular dynamics simulation studies were used to help rationalize the results.  We also report 
for the first time the ability of a B12-insulin conjugate to exhibit dose dependence in STZ diabetic 
rats.  
2.2 Results and Discussion 
 2.2.1 Synthesis of B12-B
1
Insulin (1) and B12-B
29
Insulin (2) 
Reaction of B12 with 1, 1’-carbonyl-di-(1, 2, 4-triazole) (CDT) furnished an activated 
ester at the 5’-hydroxyl group (Figure 20), as previously reported by Russell-Jones et al.19 
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Figure 20.  The activation of B12 occurs at the 5’-hydroxyl group of the ribose with the aid of 
CDT.  B12Act = CDT activated B12. 
 
The synthetic procedures for 1 and 2 were identical unless otherwise noted (see Figure 
21).  The activated B12 was added to a slowly stirring solution of bovine insulin in dimethyl 
sulfoxide (DMSO) with 0.1% triethylamine (TEA).  The site directed B12 conjugation utilizes the 
established difference in reactivity of the amino groups (LysB29 >GlyA1 >> PheB1) of insulin 
at pH 9.5.16  For 1, the more reactive LysB29 and GlyA1 were initially protected with t-
butyloxycarbonyl (BOC) to allow for specific conjugation of B12 at the unprotected PheB1 
residue as previously described by Kim et al.16  2 was synthesized without need for a protecting 
group due to the high level of reactivity of LysB29 under the reaction conditions chosen.  
 
60 
 
 
Figure 21.  The synthetic route of 1 and 2 are outlined.  
 
 Both reactions were extracted with the addition of diethyl ether and centrifugation.  The 
products were isolated by analytical reverse-phase high pressure liquid chromatography (RP-
HPLC).  Purification proved challenging due to the similarity in hydrophobicity of unconjugated 
insulin and B12 conjugated insulin.  For 1, the BOC protection was adequate to produce a 
separation between B12 conjugated and free insulin (see Figure 22).  At a pressure of 71 bar, 
HPLC yielded a dark red fraction at rt = 1.4 min, pink fractions at 7.4 and 8.5 and clear fractions 
at rt=7.6, 8.1, 9.0 and 9.7.  The pink fraction at 7.4 is B12 attached at the GlyA1 position with 
BOC at the LysB29.  However, baseline separation was not achieved and the sample contained 
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BOC-Insulin, which eluted at 7.6.  The pink fraction at 8.4 is B12 attached at PheB1-BOC
2
-
Insulin and the clear fraction at 9.0 is BOC
3
-Insulin. 
 
Figure 22.  The RP-HPLC spectra of a BOC protected insulin plus B12 reaction monitored at 254 
nm. 
 
For 2, addition of an excess of N-(9-Fluorenylmethoxycarbonyloxy) succinimide 
(FMOC-OSu) was used to aid in purification. The FMOC moiety increases the retention time of 
the unconjugated (hence, unprotected) insulin allowing for separation (see Figure 23). 
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Figure 23. The RP-HPLC spectra of an FMOC protected insulin plus B12 reaction monitored at 
360 nm (Dash, indicating B12 is present) and 254 nm (Solid, indicating insulin is present). 
 
Following HPLC purification, the protecting groups (BOC or FMOC) were removed with 
trifluoroacetic acid (TFA) (1) or piperidine (2) and dialyzed against 5 L of H2O overnight in 
7000 MWCO dialysis tubing. 
2.2.2 MALDI-ToF Mass Spectrometry 
 Matrix assisted laser desorption ionization time of flight (MALDI-ToF) mass 
spectrometry (MS) detects ions.  Therefore, the neutrally charged B12 must fragment in order to 
produce detectable species.  Experimentation with cyanocobalamin demonstrated fragmentation 
of B12 occurs with the initial loss of the cyanide group.  This is believed to result from the 
hemolytic cleavage of the Co-CN bond and subsequent protonation of the negatively-charged 
phosphate producing a [B12-CN+H]
+
 species with a 1329 m/z.20  
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The exact site of B12 conjugation was verified by MALDI-ToF MS analysis of reduced 
and digested fragments of 1 and 2.  The conjugates were first treated with dithiothreitol (DTT) to 
reduce the interchain disulfide bonds linking the A- and B-chain.  MS analysis of the reduced 
conjugates displayed m/z values of 2339 and 4755 corresponding to unmodified A-chain and 
[B12-CN+H]
+ 
bound to the B-chain, respectively (see Figure 24).   
 
Figure 24. A representative MALDI-Tof MS spectrum of DTT reduced 1 or 2 shows mass at 
4754 m/z representing [B12-CN+H]
+
attached to the B chain of insulin. Absent is B12 attached to 
the A strand, 3694 m/z. 
 
To verify the specific B chain site, reduced conjugates were treated with trypsin, which 
cleaves peptides at the carbonyl side of arginine or lysine, except when followed by proline.21  
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Reduced and digested 1 displayed a m/z of 3844 corresponding to B1-B22 plus [B12-CN+H]
+
 
indicating conjugation at the B1 site (see Figure 25 b).  While, reduced and digested 2 displayed 
a m/z of 2286 corresponding to B23-B30 plus [B12-CN+H]
+
, indicating attachment at the B29 
site (see Figure 25 a). 
 
Figure 25. (a) MALDI-Tof MS spectrum of reduced and tryptically digested 1 produces a 2286 
m/z fragment consistent with [B12-CN+H]
+
 attached to the LysB29 position.  (b) Reduced and 
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tryptically digested 2 produces a 3844 m/z fragment consistent with [B12-CN+H]
+
 at the N-
terminus of the B strand, as expected with PheB1 conjugation. 
 
 2.2.3 Electronic Absorption Spectrometry  
 B12 (CNCbl) has a distinguishable electronic absorption spectrum, which provides 
experimental data on the nature of the axial ligands, the cobalt oxidation state and the 
concentration of the B12 solution.  The absorption spectrum, seen in Figure 26, is characterized 
by two prominent bands, the α/β in the visible region and the γ band in the UV region.  All the 
prominent bands above 300 nm have been attributed to π to π
*
 transition of  the corrin ring.22  
Electronic absorption spectroscopy is a useful technique to determine the initial effects of 
synthesis on the vitamin B12 structure and the overall yield of the reaction. 
 
Figure 26.  The “typical” absorption spectra of CNCbl.  The predominate bands highlighted (α, 
β, and γ) are due to spin allowed intraligand charge transfers of the corrin ring.  
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Representative absorption spectrum for the B12 insulin conjugate is shown in Figure 27.  
From this spectrum we can determine the B12 is a Co (III) “base on” species and using Beer-
Lambert law the concentration of the solution and subsequent yield of the reaction can be 
determined using an extinction coefficient of 27500 M
-1
 cm
-1
 for the band at 361 nm.   
 
Figure 27.  The electronic absorption spectra of B12-insulin conjugates contain the characteristic 
B12 peaks and insulin peak.  
 
 2.2.4 In vivo experimentation 
 The dose dependent effect of 1 on blood glucose was assessed in STZ-rats and the results 
are shown in Figure 28.  1 was administered at concentrations of 10
-9 
M (n=3), 10
-7 
M (n=3) and 
10
-5 
M (n=2).  Area under the curve (AUC) was calculated for each dose as 1387 ± 297, 795 ± 
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202 and 125 ± 15 mmol/l 240 min below pre-gavage blood glucose concentration for 10
-9 
M, 10
-7 
M and 10
-5 
M doses, respectively.  AUC of raw data identified a significant difference between 
10
-9 
M and 10
-5 
M conditions, but there were no significant differences between the other 
concentrations.  The data presented in Figure 28 demonstrates the ability of the conjugate to 
produce a dose dependent reduction in blood glucose.  An increase in concentration from 10
-9 
M 
to 10
-5 
M resulted in an increase of 10-20% drop in blood glucose.  
 
 
Figure 28. Relative (% change from pre-gavage) blood glucose concentration following 
administration of 1 at concentrations of 10
-9 
M, 10
-7 
M and 10
-5 
M ( n = 3).  
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 Comparison of the conjugates was assessed by measuring blood glucose concentration 
following oral delivery of 1 and 2 (see Figure 29).  AUC transformation showed a significant 
difference (p=0.03) between 1 and free insulin control, consistent with that observed in our 
earlier report.
12
  Of interest here is that no significant difference in glucose drop (p=0.53) was 
observed between 1 and 2.  Both produced similar and greater drops over free insulin of the same 
orally administered concentration.  This data differs from previous literature15, 18  that suggests 
conjugation position alters the biological activity of insulin and was not what we expected.  We 
believe our findings may be explained by components of the B12 uptake pathway, making this 
result not in conflict with these earlier findings but rather suggesting a unique result tied to the 
use of B12 in insulin conjugation.  
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Figure 29.  Relative (% pre-gavage) blood glucose concentration following administration of 
free insulin (n=4), 1 (n=6) and 2 (n=6). 
 
 To help explain the biological similarities between conjugates, molecular dynamic (MD) 
simulations of TCII interacting with 1 was performed by collaborator Dr. Damian Allis of 
Syracuse University (see Figure 30).  Previous MD simulations, performed by Dr. Damian Allis, 
of 2 interacting with TCII11, 23 indicated that the lysine side chain provided an adequate tether 
length to place the unstructured insulin B-chain region (residues B20-B30) beyond the steric 
congestion of the B12 bound TCII structure.  Furthermore, the B20-B30 tail provides 
considerable length for placing the most structured region of the insulin molecule (the complete 
A-chain and B7-B19 B-chain region) far from the α and β domains of TCII, thereby not 
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impacting the binding geometry of the B12 in its internal TCII pocket or the interaction of insulin 
with the insulin receptor. 
 Formation of 1 places the B12 several residues from the structured region of insulin (the 
complete A-chain and B7-B19 B-chain region), but the effective separation of the structured 
insulin region from the TCII binding area is not obvious from the components themselves given 
(i) the inability to predict whether an accommodation for the B12 binding within its pocket will 
occur by insulin unfolding of the B1-B7 region and (ii) the inability to predict if the 
phenylalanine side chain itself would serve as a source of steric congestion to disrupt B12 binding 
in its pocket (in 2, the lysine side chain is itself the tether region between B12 and insulin).  
Insights into the nature of the B12-insulin/TCII interaction upon PheB1 conjugation come from a 
15 ns simulation of 1 interacting with the TCII complex.  A representative of the geometry of 1 
during these simulations is shown and labeled in Figure 30 and 31.   
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Figure 30.  MD simulation of TCII bound to 1. TCII structure: α-domain (red); β-domain (dark 
blue); unstructured linkage between domains (green).  Structure of 1: B12 (yellow ball and stick) 
with Co (III) (blue sphere); Insulin B-chain (yellow ribbon); A-chain (light blue ribbon).  The 
structure was produced using the GROMACS software package with GROMOS96 (53a6) 
united-atom force field by collaborator Dr. Damien Allis at Syracuse University.24 
 
 From the MD simulation we are able to see that the PheB1-CysB7 (B1-B7) region of the 
B-chain is unfolded from its unmodified, native α helix geometry (see Figure 31).  The 
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disruption of α helical structure extends slightly past the disulfide linkage (CysB7).  The result of 
this unfolding is that the B1-B7 residues become the long tether that separates the insulin core 
from TCII upon binding of the B12-insulin conjugate.  This tether originates from an otherwise 
stable α helix and is slightly longer than half of the length of the B20-B30 tether in the previous 
study.  The retention of the B12 within its binding pocket with no observable deformation of this 
pocket indicates that the B1-B7 tether is long enough to separate the two larger fragments.  It is 
this uncoiling of the B1-B7 region, induced upon binding by B12 uptake proteins that possibly 
explains why both sites on insulin ultimately equate in function and why such differences were 
not observed before. 
73 
 
 
Figure 31. A representative structure of 1 bound within TCII.  The structure was produced from 
a molecular dynamic simulation performed using the same software as previously described in 
Figure 30 by collaborator Dr. Damien Allis at Syracuse University.24 
 
2.3 Conclusion 
 We report herein on the synthesis, purification and characterization of a new B12 insulin 
conjugate attached at the insulin PheB1 position.  The hypoglycemic properties resulting from 
oral administration (gavage) of such a conjugate in STZ diabetic rats was similar to that noted in 
a B12-insulin conjugate covalently linked at the insulin LysB29 residue,
10 demonstrating the 
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availability of both positions of insulin for, at least, B12 attachment.  A possible rationale for this 
result is put forward from MD simulations, which suggest there is forced un-coiling of the 
insulin molecule at either the N- or C-terminal B strand insulin regions, depending on B12 
conjugation, upon B12 binding protein interaction with 1 or 2.  We also conclude that there is a 
dose dependent response that can be observed for B12-insulin conjugates with doses of conjugate 
greater than 10
-9
 M necessary to observe a drop in glucose.  
 In our earlier report on the oral activity of 2, it was demonstrated that the blood glucose 
reduction could be blocked by the addition of a large excess of free B12.
10  However, the 
administered amount of conjugate (13.56 μg B12) was in great excess of the expected B12 uptake 
capacity of the rat (1.5-2.0 μg per dose),13 signifying an alternative or additional mechanism for 
the response may be possible.  Given the presence of an insulin receptor in the intestine,25 it may 
be that there is an alternate receptor at play in the uptake of B12-insulin.  While the intestinal 
insulin receptor was not the intended target for our conjugates it is possible that the conjugation 
of B12 has resulted in predominantly monomeric insulin (necessary for CD220 binding) capable 
of interacting with the intestinal insulin receptor. 
 It is also possible that B12 conjugation is greatly improving insulin stability, presumably 
as IF-B12-insulin formed in situ.  This hypothesis is more consistent with the observed glucose 
drop along with observed dose-dependent response.  The blocking of uptake by large excess of 
B12 would not then be a consequence of cubam binding competition but rather prevention of IF 
binding and any associated protection.  It is also possible that the excess B12 altered the 
oligerimization of the conjugate (‘modifying the formulation’) disrupting any B12 uptake and/or 
insulin receptor binding in the intestine.  If such a route through the insulin receptor is made 
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available by B12 conjugation it would be a paradigm shift in our viewing of the exploiting of B12 
for oral protein delivery. 
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Chapter 3 Exploring the effect of B12 on glucagon-like peptide-1 biological activity 
3.1 Introduction 
 DM is characterized by a deficiency in pancreatic β cell function and mass.1  In T1D, an 
autoimmune disease has completely destroyed β cells and the body is no longer able to produce 
the hormone insulin.2  T1D will not be discussed further in this chapter.  In T2D, the pancreatic β 
cells are not producing enough insulin to meet the body’s insulin demand and as the disease 
progresses, the loss of β cell mass increases the insulin deficiency.  A primary goal of research in 
T2D diabetes is increasing the amount of functional insulin secreting β cells and slowing or 
stopping the progression of the disease.1  
 GLP-1 (7-36) amide is a 30 amino acid amidated peptide, often referred to as GLP-1, that 
has gained a lot of attention in recent years because of its physiological role in the growth of β 
cells and suppression of β cell apoptosis.3  GLP-1 also has a wide variety of physiological roles 
centered on the postprandial homeostasis of glucose, including the secretion and promotion of 
insulin and suppression of glucagon production.4, 5  GLP-1’s insulinotropic functions are glucose 
dependent, making it an ideal treatment for hyperglycemia since hypoglycemia is unlikely to 
occur.4-6  Furthermore, GLP-1 has been associated with appetite suppression,7 which is an 
important observation considering T2D is highly associated with obesity.8 
 There are two biologically active forms of GLP-1: GLP-1 (7-36) amide and GLP-1 (7-
37), which refers to the amino acid residues making up the structure and whether the C-terminal 
is amidated (see section 1.2.2.2).  The C-terminal amidation is the prominent form of GLP-1 in 
circulation, with the amidation predicted to increase stability.
9, 10
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 The therapeutic potential of GLP-1 receptor (GLP-1R) targeting for the treatment of T2D 
has been validated through extensive basic, clinical and translational research.11, 12  The 
therapeutic use of GLP-1 is limited by a short half-life (1-2 min), due primarily to degradation by 
the enzyme dipeptidyl peptidase IV (DPP-IV).4  There is however currently a GLP-1 based 
therapeutic available for the treatment of diabetes known as liraglutide.13  Liraglutide is an 
injectable medication that exhibits an increased resistance to DPP-4 degradation due to the 
addition of a fatty acid moiety at Lys26.13  Although effective for the treatment of T2D,13 the 
injectable liraglutide does not have the ability to mimic the natural secretion of GLP-1, which 
may have physiological benefits yet to be observed.   
 GLP-1 is secreted from intestinal L cells in response to orally ingested fats and 
carbohydrates and enters the systemic circulation via intestinal capillaries draining into the 
hepatic portal vein.14  GLP-1 is rapidly degraded by DPP-IV and only 10-15% of secreted GLP-1 
makes it intact into the systemic circulation.14  GLP-1 is therefore believed to be most 
concentrated in the intestinal extracellular space and hepatic portal vein.  While it has been 
established that the physiological effects of GLP-1 are a result of interaction with the GLP-1R, it 
is unclear the exact mechanism and population of GLP-1Rs responsible for the various 
physiological effects.15  GLP-1R is expressed on the vagal afferent fibers of gastrointestinal and 
hepatoportal origin, pancreatic β cells and within CNS neurons.15  
 As the potential of GLP-1 therapeutics is realized, a drug delivery system that can mimic 
the physiologic route of endogenous secretion is essential in fully understanding the mechanism 
of the GLP-1.16  It has been reported that GLP-1 acts on the afferent receptors near the site of 
secretion.7  Since native GLP-1 is secreted by the intestinal L cells, an orally delivered GLP-1 
would have the potential to mimic the full physiological effects of native GLP-1.16   
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 As a peptide, GLP-1 cannot be delivered orally due to degradation and proteolysis in the 
gastrointestinal tract.17  The B12 uptake pathway, previously discussed in chapter 1 (section 
1.4.4), has the potential to overcome these barriers and orally deliver GLP-1.  The full potential 
of the B12 uptake pathway as a delivery system has yet to be fully realized.  A number of 
limitations to this delivery strategy have been identified in recent years, including a limited 
uptake capacity and slow delivery rate, which has discouraged research into this area.18  The 
critical component to the success of the B12 delivery approach is the use of a peptide that has a 
therapeutic window within the B12 uptake capacity . 
 Using the B12 pathway for the delivery of peptides has a number of major advantages 
over other delivery systems including oral delivery, no known toxicity and the ability to cross the 
blood-brain barrier.19, 20  The limited uptake capacity of the B12 uptake pathway refers to the 
transfer of B12 from the ileum to the systemic circulation through IF-mediated endocytosis via 
the cubilin receptor (see section 1.4.7 for discussion on the cubilin).  It is important to note that 
cubilin recycles every few hours, and as such, multiple dosing (e.g., morning and evening) may 
be adopted to increase the quantity of peptide absorbed throughout the day.21 This recycling may 
also be important when considering dietary B12 competition.   
 We have previously demonstrated the ability to use B12 to orally delivery clinically 
relevant amounts of the appetite suppressant peptide tyrosine tyrosine (PYY).22  To adapt this 
uptake pathway for the delivery of GLP-1, recognition and affinity for the various binding B12 
transport proteins must be maintained and the biological potency of the GLP-1 must not be 
diminished.  We are now exploring in depth the effect of B12 conjugation on the biological 
potency of GLP-1 in an attempt to demonstrate the true potential of the uptake pathway for the 
delivery potent peptides and proteins. 
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3.2 Results and Discussion 
3.2.1 Synthesis and Purification of B12-K34R-GLP-1 (7-36) amide (3) 
GLP-1 (7-36) amide has three amine groups (N-terminal, Lys26 and Lys34) available for 
conjugation.  For our lead conjugate, the peptide was purchased with modifications (amino acid 
substitution K34R, and FMOC protection of the N-terminal amine (FMOC-K34R-GLP-1)) to aid 
in selective conjugation at the Lys26 (Figure 32).  No significant reduction in biological activity 
has been shown for conjugation at the Lys26.23, 24  Commercially available Liraglutide has the 
same amino acid substitution24, 25 and the FMOC protection was removed after synthesis.  
 
Figure 32.  GLP-1 (7-36) amide was purchased with N-terminal FMOC protection and K34R 
amino acid substitution (34) which will be referred to as FMOC-K34R-GLP-1 or K34R-GLP-1 
when the FMOC is removed.  These modifications allow for site directed B12 conjugation at the 
Lys26 (26).   
 Modifications at the 5’-hydroxyl group of B12 have been repeatedly shown to maintain 
binding with the transport proteins vital for oral B12 uptake.
22, 26, 27
  Reaction of B12 with 1,1’-
carbonyl-di-(1,2,4-triazole) in DMSO at room temperature for 5 minutes furnished an activated 
ester at the 5’-hydroxyl group.  An excess of activated B12 was then added to a slowly stirring 
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solution of FMOC-K34R-GLP-1 in DMSO with 0.1% TEA.  The reaction proceeded for 3 hrs 
before an excess of FMOC-OSu was added to help with purification, as described below.  
 The reaction was extracted by diethyl ether addition and centrifugation. The product was 
isolated on a C18 analytical column using reverse phase HPLC.  Unreacted B12 was easily 
separated from FMOC-K34R-GLP-1, however purification of unconjugated FMOC-K34R-GLP-
1 and B12 conjugated FMOC-K34R-GLP-1 proved challenging due to the similarity in 
hydrophobicity.  The addition of excess FMOC-OSu was used to aid in purification, as 
previously reported for a B12 insulin conjugate.
27
  The FMOC moiety increases the retention time 
of the unconjugated (hence, unprotected) FMOC-K34R-GLP-1, allowing for separation (see 
Figure 33).  Following HPLC purification, the protecting group was removed with piperidine and 
dialyzed against 5 L of H2O overnight in 3500 MWCO dialysis tubing. A 10% yield of 3 was 
calculated using electronic EAS with an extinction coefficient of 27500 M
-1
 cm
-1
 at 361 nm, 
corresponding to the B12 γ band, as described in section 2.2.3.  
 
Figure 33. RP-HPLC chromatogram showing separation of unconjugated B12 and K34R-GLP-1 
from B12 conjugated K34R-GLP-1 with detection at 254 nm (solid line) and 360 nm (dash line). 
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Absence of B12 absorption at 360 nm indicated the peak at retention time (Tr) ~ 24 mins is 
unconjugated K34R-GLP-1 now with two FMOC units, while the peak at Tr ~ 20 mins is B12 
conjugated K34R-GLP-1 with one FMOC.  
 
3.2.2 MALDI-ToF Mass Spectrometry 
B12-FMOC-K34R-GLP-1 was identified as the peak at a Tr of 20 by MALDI-Tof MS.  
The peak at 4682 m/z represents a 1:1 [B12-CN+H]
+
 K34R-GLP-1 conjugate (see Figure 34).   
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Figure 34.  MALDI-ToF MS spectrum of 3 after FMOC removal showing the presence of a 
prominent peak at 4682 m/z representing a 1:1 B12-K34R-GLP (7-36) amide. 
 
3.2.3 In vitro Experimentation  
GLP-1 mediates its insulinotropic effects by binding to specific GLP-1 receptors on the 
pancreatic β cells and stimulating cAMP formation, calcium induced calcium release (CICR) and 
insulin secretion (see Figure 35).15  The effect of B12 conjugation on GLP-1 physiological 
function (cAMP production, CICR and insulin secretion) was studied in HEK-293 cells stably 
expressing the human GLP-1 receptor (HEK-GLP-1R) and isolated human pancreatic islets.  
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Figure 35.  A basic depiction of the intercellular mechanisms of the GLP-1R, which were 
monitored for in vitro assays described in section 3.2.5.  RYR: ryanodine receptor; ER: 
endoplasmic reticulum; CRE: cAMP response element. RIP-1-CRE-Luc: rat insulin 1 promoter-
cAMP response element-luciferase reporter. 
 
To determine the ability of the conjugate to perform as a cAMP elevating agent, HEK-
GLP-1R cells were transfected with a reporter construct containing the coding sequence for the 
luciferase (Luc) enzyme and a promoter incorporating a cAMP response element originally 
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identified within the 5’ promoter region of the rat insulin 1 gene (RIP1-CRE).28  This cAMP-
responsive Luc reporter (RIP1-CRE-Luc) can be used to determine the effect of agonist for G 
protein-coupled receptors positively linked to cAMP production, such as the GLP-1 receptor.28 
The level of Luc activity was determined in whole-cell lysates by Luc-catalyzed oxidation of 
luciferin, which generated photons detected by a photomultiplier tube. After exposure to the drug 
for 4 hrs, Luc activity was determined and shown to be concentration dependent with an EC50 of 
4.4 nM (see Figure 36).  These findings were comparable to that found for K34R-GLP-1 with an 
EC50 of 4.1 nM (see Figure 36).  B12 was not shown to produce any response in the luciferase 
assay.  The EC50 values suggest the B12 has little negative effect on the potency of the GLP-1, an 
important and highly positive result.  
 
Figure 36.  The fold increase of luciferase activity was determined for 3 and K34R-GLP-1 after 
HEK-GLP-1 cells were transfected with a RIP1-CRE-Luc reporter and were exposed to 3 for 4 
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hrs. 3 produced a concentration dependent response with an EC50 of 4.4 nM, while K34R-GLP-1 
had an EC50 of 4.1 nM. 
The stimulatory effects of GLP-1 on pancreatic islet insulin secretion have been 
attributed to the capability to increase levels of cytosolic [Ca
2+
] in β cells.15, 29  GLP-1 produces a 
rise in cytosolic [Ca
2+
] by promoting CICR from intracellular storages.15  The ability of 3 to 
facilitate an increase in cytosolic [Ca
2+
] was assessed in HEK-GLP-1R cells that express 
endogenous P2Y purinergic receptors using a fura-2 assay.  Fura-2 is a widely used ratiometric 
fluorescent dye which is used to determine intercellular levels of calcium.  Fura-2 determinations 
of [Ca
2+
] were obtained in a 2-step injection protocol were 3 (A) or native GLP-1 (B) was 
administered to each well after baseline recording for 100 s.  After a further 200 s the P2Y 
receptor agonist adenosine diphosphate (ADP) (10 nM) was added and the ratio of Fura 2 was 
recorded.  Both forms of GLP-1 potentiated the action of ADP to mobilize intracellular [Ca
2+
] 
and native GLP-1 was slightly more potent than 3 (see Figure 37). 
 
 
87 
 
 
Figure 37.  Fura-2 determinations of intercellular [Ca
2+
] were obtained in HEK-GLP-1R cells 
that express endogenous P2Y purinergic receptors.  Note that both forms of GLP-1 potentiated 
the action of ADP to mobilize intracellular [Ca
2+
] and that native GLP-1 was slightly more potent 
than 3. Data are averaged from 12 wells for each data point and similar results were obtained in 
four independent plates with three different batches of 3.  
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 Since its formation in 2001, the national Islet Cell Resource (ICR) Center Consortium has 
provided isolated human pancreatic islets (see Figure 38) for clinical and basic research while 
also working to develop methods to perfect the isolation of islets for human transplantations.30  
Human pancreatic islets are a critical tool for diabetes researchers.  Human islets have provided 
invaluable information about the cellular biology of the pancreas and the pathology of diabetes.  
Furthermore, the uniqueness of the human pancreatic biology is an invaluable tool for the 
development of therapeutics for the treatment of diabetes.30  
 
Figure 38.  Pure human pancreatic islets isolated from digested pancreatic tissues, as seen under 
a microscope.  Image reprinted from reference 31 with permission of Baishideng Publishing 
Group Co. 
 To evaluate potential insulin secretagogue properties of B12-GLP-1, human islet insulin 
secretion was monitored under standard conditions of static incubation in which human islets 
were equilibrated in Krebs-ringer buffer (KRB) containing 2.8 mM glucose, followed by a 
subsequent elevation of the glucose concentration to 16.7 mM with or without the test substance.  
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The rise in glucose concentration will cause glucose stimulated insulin secretion (GSIS) in 
healthy insulin producing islets and the addition of a GLP-1 based conjugate should increase the 
GSIS.  The initial GSIS was used to determine the viability of the human islets being tested.  
Human islets used for basic research are not healthy enough for human transplantations, which 
means they are not always viable for research purposes either.   
  The average of three batches of isolated human islets produced a GSIS of 2.2-fold 
insulin secretion (see Figure 39).  GSIS was potentiated an additional 45% by 15 nM 3 (total 3.2 
fold stimulation).  This effect of 3 was similar to that which was measured when islets were 
instead treated with 15 nM GLP-1 (total 3.3 fold stimulation).   
 
Figure 39.  Static incubation assays using human pancreatic islets. Islets were exposed to KRB 
containing 2.8 mM glucose for 30 min and were then exposed to KRB containing 16.7 mM 
90 
 
glucose with GLP-1 or 3 or without test substance.  GSIS resulted in a 1.4 fold insulin secretion 
while a 3.2 fold increase was observed for 3, which is comparable to the GLP-1 (3.3 fold 
increase). 
 
3.3. Conclusion 
 We have reported on the synthesis, purification and in vitro characterization of a novel 
B12-K34R-GLP-1conjugate.  Experimentation with the lead B12-GLP-1 conjugate in vitro 
demonstrated B12 attachment has a minimal effect on the insulinotropic nature of K34R-GLP-1 
(EC50 4.1 nM vs. 4.4 nM).  We analyzed various steps in the physiological pathway of GLP-1 
stimulated insulin secretion to come to this conclusion.  Initially we used a luciferase based assay 
to indirectly determine the ability of 3 to produce an increase in intercellular cAMP levels.  The 
ability of B12-GLP-1 to stimulate CICR was than monitored by Fura-2 assay.  Finally we used 
transplanted human islets to confirm the ability of B12-GLP-1 to stimulate insulin secretion.  This 
is the first reported study of how B12 conjugation affects a peptide’s in vitro activity.  The data 
collected for the B12-GLP-1 conjugate in vitro are very encouraging.  The next step is in vivo 
experimentation to determine the biological activity of the B12-GLP-1 conjugate, which is 
scheduled to occur in October 2012 in the lab of collaborator Dr. Christian Roth in Seattle 
Children’s Hospital, WA, US. 
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Chapter 4 Synthesis of a B12 Derivative Capable of Amide Bond Formation  
4.1 Introduction 
The increasing use of B12 for the delivery of therapeutics has encouraged the re-
examination of potential conjugate sites of B12.
1-4  Several positions are available on B12 
for conjugation, including the 5’-hydroxyl group of the ribose, the cobalt (III) ion, the 
phosphate moiety and propionamides off the corrin ring (if modified to a carboxylic acid 
first) (see Figure 40).5-7  Numerous groups have explored modifications of B12 that allow 
for more facile, higher yielding or stable conjugate formation with continued recognition 
by B12 dietary transport proteins.
1, 3, 8-23  All such modifications to date suffer from issues 
including reduced or complete loss of interaction with one or more of the B12 binding 
proteins, stability issues that result from the production of ester or carbamate bonds, low 
yielding conjugation reaction due to the nature of the functional group, or require 
problematic purification of the modified B12 for subsequent conjugation.
1, 3, 8-23  These 
limitations have been well investigated24-26 and reviews of such sites has been reported,27-
30 however, in brief for purposes of perspective for the work described herein:  
 Conjugation resulting in the recognition of all three transport proteins has been 
most successful with B12 at two major sites: 1) the 5’-hydroxy group of the ribose group 
and 2) the peripheral corrin ring e propionamide (see Figure 40).  The side chain e 
carboxylic acid derivative, produced from hydrolysis of the propionamide, allows for a 
variety of modifications,31-33 but the synthesis of the derivative is low yielding and 
requires a laborious purification, the result, in part, of the formation of b and d carboxylic 
acid isomers in addition to the desired e carboxylic acid derivative.34-38  The 5’-hydroxyl 
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group of the ribose is a versatile site according to structure-activity relationships, 
however conjugates produced have typically been synthesized, as mentioned above, 
through carbamate or ester bonds.  
 
Figure 40.  Potential sites available for carboxylic acid formation that also maintain, at 
least in part, B12 uptake protein recognition and binding are indicated in red.  The atom 
numbering scheme used for future NMR discussion (see section 4.2.2) is also indicated.  
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We report the selective oxidation of the 5’-hydroxyl group of B12 to the 
corresponding carboxylic acid using a hypervalent iodine reagent, 2-iodoxybenzoic acid 
(IBX).  IBX (see Figure 41) has never been utilized for the oxidation of such a complex 
molecule as B12.  The work reported here expands the range of successful use of the 
environmentally friendly oxidizing agent.39 
 
Figure 41.  The structure of 2-iodoxybenzoic acid (IBX).  
 
4.2 Results and Discussion 
 4.2.1 Synthesis of B12 5’-carboxylic acid (4) 
The B12 5’-carboxylic acid (4) was synthesized utilizing a modified method of 
Giannis et al., which incorporates the addition of an O-nucleophile to aid IBX in the 
transformation of a primary alcohol to a carboxylic acid (see Figure 42).40, 41 
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Figure 42.  Purposed mechanism for the formation of 4 utilizing IBX and 2-
hydroxypyridine (HYP).  
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 The use of the O-nucleophile N-hydroxysuccinimide (NHS) was initially 
attempted, but resulted in an inability to isolate the carboxylic acid, likely due to the 
formation of the activated NHS ester that has been reported as a dominating product of 
this reaction.40, 41  2-hydroxypyridine (HYP) was used as the O-nucleophile. To optimize 
the reaction conditions, a series of experiments were performed where co-oxidant, 
temperature and time were varied (see Table 2).   
Table 2.  Optimization of the Reaction Conditions for 4. 
Entry Co-Oxidant Temp (
o
C) Time (hr) Yield (%) 
1 None 50 2 17 
2 HYP 50 2 23 
3 HYP 50 3 26 
4 HYP 50 4 28 
5 HYP 50 5 22 
6 HYP 60 2 30 
 
 The best result was obtained in the presence of 2.6 equivalents of IBX and 5 
equivalents of HYP in DMSO at 60 
o
C.  These conditions resulted in the oxidation of B12 
to the 4 in two hours with a 30% yield.  It was determined that a 30% yield was optimal 
for the IBX reaction, in this case, as increase in temperature, IBX/HYP ratios or time 
resulted in an increase in byproducts and/or decomposition of the B12 (especially at 
temperatures in excess of 60 
o
C), and which also co-eluted with the desired carboxylic 
derivative, complicating purification.  The 30% yield is ~ three times that previously 
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reported for the preparation of the e-carboxylic acid derivative and with far easier 
separation (vide infra). 34-38  
The crude reaction was precipitated from DMSO by diethyl ether addition and 
dissolved in H2O prior to purification by ion exchange chromatography using a SAX 
column.  After a 5 minute hold at 100% water, a gradient from 100% water to 35% 
MeCN:phosphate buffer pH 2 (50:50 v/v) over 5 minutes was necessary for the 
separation and elution of 4 (see Figure 43).  Slight increases in pH above 2 resulted in a 
loss of pure product isolation.  The HPLC purification allowed for the recovery and reuse 
of B12 starting material, albeit with the oxidized 5’-aldehyde also present (see Figure 43).  
4 was identified as the peak at retention time (Tr) 13.5 mins.  Purity of 4 was at least 95% 
as assayed by RP-HPLC. 
 
Figure 43.  The RP-HPLC spectra of 4 (Tr = 13.5 mins.) monitored at 360 nm.  
Unreacted B12 and 5’aldehyde co-elute at ~ Tr = 6 mins as indicated by MALDI-ToF MS.
 
MALDI-Tof mass spectrometry analysis of 4 demonstrated the anticipated 
molecular ion peak [M-CN]
+ 
 of 1343.5 m/z (see Figure 44). 
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Figure 44.  MALDI-ToF MS spectrum of HPLC peak at Tr =14 mins indicating 4 ([M-
CN]
+
 1343.5 m/z) with angiotensin as an internal reference.  
 
Electronic absorption spectroscopy (EAS) was used to determine the oxidation 
state of the metal center, nature of the axial ligands bond to the metal center and yield of 
CA (ε
CA
361 = 27500 M
-1
 cm
-1
) (see Figure 45). 
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Figure 45.  Absorbance spectrum of 4 in 35 % HPLC mobile phase B. 
  4.2.2 1D and 2D NMR analysis of 4 
The structure of 4 was determined by assignments obtained from 
1
H NMR (see 
Figure 46) and 
1
H-
13
C heteronuclear (HSQC and HMBC) correlations (see Figures 47 
and 48).  The 
1
H NMR spectra of 4 revealed the loss of 2 protons (δH = 3.75 and 3.92), 
when compared to the spectrum of B12 (CNCbl) (see Figure 49).  A comparison of the 
HSQC of B12 and 4 indicates the protons lost in 4 were originally attached to the R5 
carbon (δC = 63.3) (see Figure 50).  HMBC was then chosen to further establish the 
addition of a carbonyl at the R5 position (see Figure 48), however it was established that 
the R5 carbon shows no connectivity to any of the ribose protons and so was assigned by 
HSQC.42
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Figure 46.  500 MHz 
1
H NMR spectrum of 4. 
. 
Figure 47.  500 MHz 
1
H-
13
C HSQC NMR spectrum of 4. 
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Figure 48.  500 MHz 
1
H-
13
C HMBC NMR spectrum of 4. 
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Figure 49.  500 MHz 
1
H NMR spectrum of B12 (CNCbl). 
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Figure 50.  Portion of HSQC of 4 (right) and B12 (left) highlighting the loss of protons 
(δH = 3.75 and 3.92) due to oxidation at the R5 carbon (δC = 63.3) in the 4.  
 
  4.2.3 Synthesis and Characterization of B12-5’-carboxylic acid 
benzylamine (5) 
A simple amine containing organic molecule, benzylamine, was conjugate to the 
derivative to help with the identification of the R5 carbon by NMR. In the presence of 10 
equivalents of ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and 20 equivalents 
1-hydroxybenzotriazole (HOBt) in DMF with 1% H2O, the desired conjugate was 
produced within 1 hour at 40% yield (Figure 51).  
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Figure 51. Synthesis of 5.  
5 was purified using the same purification method as established for the 
carboxylic acid (see Figure 52) and characterized by MALDI mass spectrometry (see 
Figure 53) as well as 1D (see Figure 54) and 2D NMR (see Figure 55 and 56). 
 
Figure 52. Purification of the conjugate was established by RP-HPLC using an SAX 
column with a gradient from 100% water to 35% MeCN: phosphate buffer pH 2. 
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Figure 53.  MALDI-ToF MS spectrum of 5 ([M-CN+H]
+
 1432.5).  Angiotensin was used 
as an internal reference (not shown).  
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Figure 54.  500 MHz 
1
H NMR spectrum of 5. 
 
Figure 55.  500 MHz 
1
H-
13
C HSQC NMR spectrum of 5. 
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Figure 56.  500 MHz 
1
H-
13
C HMBC of 5. 
 
Figure 57.  Analysis of 5 by 2D heteronuclear NMR spectroscopy. A. The atom 
numbering scheme for the benzylamine attached to the R5 of B12 by an amide bond. B. 
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Signal assignments made from HSQC. C. Signal assignments made from HMBC (Both 
1
H and 
13
C assignment for CA were made by HSQC). 
 
Addition of the benzylamine connectivity of the R5 carbon was established by 
HMBC (see Figures 56 and  57).  Specifically the protons of CA (δH = 4.42 and 4.50 ppm) 
showed direct connectivity to the R5 carbon (δC = 173.8 ppm) as well as CB (δC = 140.8 
ppm) and CC (δC = 131.4 ppm) of the benzylamine (see Figure 57). The complete 
assignment of 4 and 5 can be found in Table 3. 
Table 3.  
1
H and 
13
C chemical shifts for the B12 5’-carboxylic acid (B12CA), B12 5’-
carboxylic acid benzylamine (B12CABA) and B12 (CNCbl) in D2O [500 MHz].  
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4.3 Conclusion 
In conclusion, we have developed a convenient synthesis for the site-specific 
oxidation of B12 using IBX and HYP.  This new carboxylic acid derivative is highly 
suited to the production of bioavailable amide bound conjugates. The one step 
purification is simplistic and the synthesis results in a 30% yield within 2 hours, which is 
far in excess of any previously reported B12 carboxylic acid derivative.
9 
The resulting 
derivative has the potential to form high yielding conjugates and we believe will be of 
considerable use for the field of B12 conjugation.  
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Chapter 5  Experimental Procedure 
5.1 Materials and Methods 
 Chemicals and solvents were purchased from Sigma–Aldrich or Fluka and were 
used without further purification.  Powdered bovine insulin was purchased from Sigma–
Aldrich.  Glucagon-like peptide (7-36) amide with a K34R amino acid substitution and 
N-terminal FMOC protection (FMOC-K34R-GLP-1) was purchased from NEOBiolab 
(Cambridge, MA).  DMSO was dried over 4 Ǻ molecular sieves (200–400 mesh, Sigma) 
under dry dinitrogen.  Dialysis tubing (2000, 3500, and 7000 Da cutoff) was purchased 
from Pierce.  H2O was distilled and deionized to 18.2 mΩ using a Barnstead Nano 
Diamond ultra-purification machine.  RP-HPLC purification was carried out on an 
Agilent 1100 system with a variety of Agilent columns discussed below.   
 MALDI-TOF MS was performed on a Bruker Autoflex III Smartbeam machine 
with laser intensity ranging from 50–73%. The matrix used for MALDI-ToF was 10 mg 
α-cyano-4-hydroxycinnamic acid (CHCA) dissolved in dH2O/CH3CN (1:1 v/v) 
containing 0.1% TFA. Angiotensin I was used as an internal control (1296 m/z). B12-
insulin conjugates were reduced with 10 mM DTT to determine  B12 attachment to A-
Chain or B-Chain. Trypsin digestion of B12-insulin conjugates was accomplished with the 
addition of 0.02 moles trypsin to a 1 mole of B12-insulin to determine what fragment of 
B-chain B12 attachment occured. EAS were obtained on a Varian Cary 50 Bio 
spectrometer in a 1 mL quartz cuvette (Sigma) between 200 nm and 600 nm.  All 
centrifugation was done at 4000 rpm for 10 minutes using a Sorvall centrifuge with a 
swinging rotor (Sorvall Heraeus 75006441 K). 96-well plates were coated with rat tail 
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collagen from BD Biosciences prior to assays.  CMRL-1066 modified culture medium 
was obtained from Mediatech.  Fetal bovine serum (FBS), Dulbecco’s modified eagle 
media (DMEM), Pluronic F-127 and Fura-2 acetoxymethyl ester (Fura-2AM) were 
purchased from Invitrogen Life Technologies, Carlsbad, CA.   Insulin secretion was 
determined using a Mercodia Ultrasensitive Rat Insulin ELISA Kit #10-1247-10.  
Measurements of intracellular [Ca
2+
] were performed using a FlexStation 3 microplate 
reader using SoftMaxPro software from Molecular Devices. A Lipofectamine 2000 kit 
was purchased from Invitrogen for transfections. A luciferase assay kit was purchased 
from Promega, Madison, WI.   
5.2 Experimental Procedures 
 5.2.1 Synthesis of B12-B
1
Insulin (1) 
 The activation of the 5’-hydroxyl group of B12 was achieved using a previous 
reported method.1  B12 (10 mg, 0.007 mmol) and CDT (1.7 mg, 0.010 mol) were stirred in 
DMSO (1 mL, dried) under dry dinitrogen for 1 h.  The activated B12 was used without 
further purification.  A variation of the literature procedure reported by Kim et al. was 
used for the BOC protection of insulin.2  BOC (4.0 mg, 0.0187 mmol) and NHS (4.4 mg, 
0.04 mmol) dissolved in DMSO (100 μL) containing 0.05% TEA (v/v) stirred for 0.5 h 
prior to being added to a stirring solution of insulin (5.0 mg, 0.00087 mmol) dissolved in 
DMSO (1 mL) containing 0.05% TEA (v/v). After 0.5 h, an excess of activated B12 (2.4 
mg, 0.0017 mmol) was added to the BOC  protected insulin solution. The reaction stirred 
for 4 h and was isolated using diethyl ether (Et2O) and centrifugation.  The red solid was 
dissolved in 25/75 (v/v) CH3CN/H2O containing 0.1% TFA and purified using analytical 
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RP-HPLC with an Eclipse XDB-C18 column (5 μm, 9.4 X 250 mm); flow rate: 1 mL/min, 
solvent A: dH2O/0.1% TFA; solvent B: CH3CN/0.1% TFA; method 0-10 min 75/25% 
A/B to 47.5/52.5% A/B.  Collected 1 was then spiked with 50% TFA (0.5 ml) and stirred 
for 0.2 h to remove the BOC protection.  1 was dialyzed against 5 L dH2O in snakeskin 
tubing (7000 Da cutoff) to remove residual free insulin and BOC.  The dialysis bag 
content was then concentrated by lyophilization overnight yielding a light pink powder 
(0.31 mg, 5%).  HPLC Tr = 8.5 mins; MALDI-ToF: calculated for C317H464CoN79O89PS6 
Insulin-[B12-CN+H]
+
 7090.9 m/z, found 7090.5 m/z; MALDI-ToF of reduced of 1: 
calculated for insulin’s B-Chain + [B12]
+
 4754.5 m/z, found 4754.5 m/z; MALDI-ToF of 
reduced and digested 1: calculated for Insulin’s B23-B30 + [B12]
+
 2285.9 m/z, found 
2285.8 m/z. Yield was calculated from EAS using ε361 =27,500 M
-1
cm
-1
.    
 5.2.2 Synthesis of B12-B
29
Insulin (2) 
 Powder bovine insulin (5.0 mg, 0.00087 mmol) was dissolved in DMSO (1 mL) 
containing 0.05% TEA (v/v).  An excess of activated B12 (2.4 mg, 0.0017 mmol) was 
transferred to the unprotected insulin and reacted for 4 hours. FMOC-OSu (0.5 mg, 
0.0015 mmol) in DMF (1 mL) was added to the reaction mixture. The reaction mixture 
stirred for 2 h and was isolated using Et2O and centrifugation. The red solid was then 
dissolved in a 25/75 (v/v) CH3CN/H2O containing 0.1% TFA and purified using 
analytical HPLC. Piperidine (10% v/v) was added to the pink fraction. Dialysis (7000 Da 
cutoff) against H2O (5L) removed residual free insulin and FMOC.  The dialysis bag 
content was then concentrated by lyophilization overnight yielding a light pink powder 
(0.62 mg, 10%).  HPLC Tr = 8.5 mins; MALDI-ToF: calculated for C317H464CoN79O89PS6 
Insulin-[B12-CN+H]
+
 7090.9 m/z, found 7090.5 m/z; MALDI-ToF of reduced of 2: 
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calculated for insulin’s B-Chain + [B12]
+
 4754.5 m/z, found 4754.5 m/z; MALDI-ToF of 
reduced and digested 2: calculated for Insulin’s B1-B22 + [B12-CN+H]
+
 3844.6  m/z, 
found 3844.6 m/z. Yield was calculated from EAS using ε361 =27,500 M
-1
cm
-1
.  
 5.2.3 Synthesis of B12-K34R-GLP-1(7-36) amide (3) 
B12 (10 mg, 0.007 mmol) was activated at the 5’-hydroxyl group using CDT (1.7 
mg, 0.010 mmol) in DMSO (1 mL, dried) under dry dinitrogen for 30 mins.  The 
activated B12 solution (0.096 mL, 0.0007 mmol) was subsequently added to a stirring 
solution of FMOC-K34R-GLP-1 (1.0 mg, 0.0028 mmol) dissolved in DMSO (0.1 mL) 
with 0.6% TEA (v/v).  The reaction stirred for 3 hrs at RT before H2O w/ 0.1% TFA 
(20% v/v) was added to the reaction to lower the pH.  A solution of FMOC-OSu (0.028 
mmol) in DMF was added and allowed to proceed an additional hr.  The reaction was 
extracted with the addition of diethyl ether.  Purification of the B12-FMOC-K34R-GLP-1 
conjugate was accomplished by RP-HPLC using an Agilent C18 column and HPLC 
method solvent A: dH2O/0.1% TFA; solvent B: CH3CN; 0-25 min 75/35% A/B to 
35/65% A/B.  The pH of the solution was adjusted to pH 8 with NH2HCO3 immediately 
following isolation by HPLC.  The removal of the N-terminal FMOC protection was 
accomplished with the addition of 10% piperidine after 10 minutes.  The solution was 
transferred to 3500 MWCO dialysis tubing and dialyzed against H2O for 18 hours, 
changing solution every 4-6 hours. 3 was collected as a light pink solution (0.10 mg, 
10%).  HPLC Tr = 19.5 mins; MALDI-ToF: calculated for K34R-GLP-1-[B12-CN+H]
+
 
4680 m/z, found 4682 m/z; Yield was calculated from EAS using ε361 =27,500 M
-1
cm
-1
.    
5.2.4 Synthesis of B12-5’-carboxylic acid (4) 
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B12 (10.0 mg, 0.007 mmol), 2-iodoxybenzoic acid (5.37 mg, 0.019 mmol) and 2-
hydroxypyridine (3.51 mg,0.037 mmol) were dissolved in DMSO (1 mL).  The reaction 
temperature (50-60
o
C) and time (2-5 hrs) were varied as outlined in Table1.  The crude 
reaction was precipitated by diethyl ether addition and dissolved in H2O prior to 
purification.  The derivative was purified by ion exchange chromatography using a SAX 
column.  After a 5 minute hold at 100% H2O, a gradient from 100% H2O to 35% MeCN: 
phosphate buffer pH 2 (50:50 v/v) over 5 minutes was necessary for the separation and 
elution of the 4. 4 was then neutralized and mixed with amberlite XAD4 resin overnight.  
The resin, now red suggesting 4 binding, was collected and washed with H2O to remove 
any salt prior to MeOH extraction of the 4.  The MeOH was collected and lyophilized 
yielding a red powder (3 mg, 30% for 2 hrs at 60
o
C).  HPLC Tr =14 mins; MALDI-TOF 
MS: calculated for C62H86CoN13O15P [M-CN]
+
 1343.5, found 1343.5; See chapter 4 table 
3 for NMR assignments.  
5.2.5 Synthesis of B12 5’-carboxylic acid benzylamine (5).  
4 (10.0 mg, 0.007 mmol), benzylamine (7.8 mg, 0.073 mmol), 1-EDC (14.0 mg, 
0.073 mmol) and HOBt (19.7 mg, 0.146 mmol) were dissolved in DMF (1 mL) with 1% 
H2O at rt for 1 hr.  Isolation and purification were achieved as described for the 4 (4.0 
mg. 40%).  HPLC Tr= 10 mins. MALDI-TOF MS: calculated for C69H93CoN14O14P [M-
CN+H]
+
 1432.5, found 1432.5; δH = 7.42, 7.41, 7.41, 7.39, 7.38 corresponding to the 
aromatics of benzylamine and 4.46 corresponding to CA. δC = 140.8, 131.4, and 46.4 
corresponding to CB , CC , and CA respectively. See chapter 4 table 3 for B12 related NMR 
assignments. 
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5.3 In vitro Investigation of 3 
 5.3.1 Cell Cultures 
 Human embryonic kidney (HEK-293) cells stably expressing the human GLP-1 
receptor were a gift of Novo Nordisk A/S (Bagsvaerd, Denmark).  HEK-GLP-1R cells 
were cultured in DMEM containing 10%  FBS, penicillin/streptomycin, and G418. The 
cells were maintained at 37 °C in a humidified incubator gassed with 5% CO2 and were 
passaged by trypsinization once per week. 
 Human islets of Langerhans, obtained posthumously from anonymous donors, 
were provided under the auspices of the Integrated Islet Distribute Program  of National 
Institutes of Health, National Center for Research Resources, and National Islet Cell 
Resource Centers.  Primary cultures of human islets were maintained in a humidified 
incubator containing 95% air and 5% CO2 at 37 °C in CMRL-1066 modified culture 
medium containing 10% (v/v) FBS.  
 5.3.2 Luciferase Assay 
 For GLP-1 activity, HEK-GLP-1R cells were plated in a rat tail collagen coated 
96 well plate at a density of 55,000-65,000 cells/well and incubated overnight at 37
o
C.  
The next day, the cells were transfected with RIP1-CRE-Luc using Lipofectamine 2000 
according to the manufacturer’s instructions.  The cells (HEK-GLP-1R-RIP1-CRE-Luc) 
were cultured in DMEM containing 10% FBS overnight, then exposed for 4 h to serum-
free culture medium containing 1% BSA and the test substance. Cells were then lysed 
and assayed for luciferase-catalyzed photoemissions using a luciferase assay kit and 
luminometer.  
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 5.3.3 Fura-2 Assay 
 The experiment was performed using a monolayer of fura-2 loaded HEK-GLP-1R 
cells grown on rat tail collagen coated Costar 3904 plate.  Fura-2 was loaded in a 
standard extracellular solution (SES) containing: 138 NaCl mM, 5.6 mM KCl, 2.6 mM 
CaCl2, 1.2 mM MgCl2, 10 mM HEPES pH 7.4 and 11.1 mM glucose.  The SES was also 
supplemented with 20 μl per ml FBS, 1 μl per ml Pluronic F-127 and 1 μM fura-2 AM.  
Spectrofluorimetry was performed using excitation light at 355/9 and 375/9 nm 
(center/bandpass) delivered using a 455 nm dichroism mirror.  Emitted light was detected 
at 505/15 nm and the ratio of emission light intensities due to excitation at 355 and 375 
was calculated.  
 5.3.4 Insulin Secretion in Human Pancreatic Islets 
 Insulin secretion was determined by static incubation.  After overnight culture in 
CMRL-1066 medium, human islets were transferred to MilliCell-PCF culture plate filter 
inserts at a density of 40 islets/insert.  The inserts were mounted within individual wells 
of a 24-well cell culture plate and each well of the plate was filled with 1 ml of Krebs-
ringer buffer (KRB) containing 24 mM sodium bicarbonate and the indicated 
concentrations of glucose (pH 7.4).  Culture plates containing islets were placed within a 
cell culture incubator gassed with 95% air and 5% CO2 at 37 °C.  Prior to the start of an 
experiment, islets were exposed to KRB with 2.8 mM glucose for 30 min.  The inserts 
were then transferred between adjacent wells on the plate to measure basal and stimulated 
insulin secretion.  For each test solution, the duration of exposure was 30 min.  A 200 μl 
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fraction of each solution was then collected and assayed for insulin content by an 
enzyme-linked immunosorbent assay after appropriate dilution of samples. 
5.4 In vivo Experimentation of 1 and 2 
Male Sprague Dawley rats (279 ± 31; ± SD; n=12) were rendered insulin-
deficient via subcutaneous injection of streptozotocin (STZ; 80 mg/kg BW) dissolved in 
citrate buffer (100 mM; pH 4.2). Blood glucose concentration was assessed after four 
days to ensure fasting levels of greater than 15 mmol/L. Maintenance of animals and 
experimental protocols were conducted in accordance with federal regulations and 
approved by the Murdoch University Animal Ethics Committee. Animals were fasted 
overnight prior to the first blood sample being taken from the lateral tail vein and 
assessed for glucose concentration (One-touch Verio).  Compounds were then 
administered by oral gavage using a flexible feeding tube and blood samples collected 60, 
120, 150, 180, 210 and 240 min post gavage from the lateral tail vein. AUC 
transformations were conducted using the trapezoidal method in SigmaPlot, which was 
then subtracted from pre-gavage[mmol] x 240min; higher numbers represent a greater 
reduction in glucose concentration following oral gavage. Statistical significance was 
then assessed on this data using a one-way ANOVA with repeated measures (condition) 
after testing for normality (Shapiro-Wilk) and equal variance. Tukey post Hoc testing 
was used to assess differences between condition. 
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Chapter 6  Future Work 
6.1 Vitamin B12 
 Major strides towards establishing the role of B12 as a carrier for oral delivery of 
protein therapeutics have been achieved.  The full potential of the B12 dietary uptake 
pathway, however, has not been completely realized.  Further exploration into the 
transport proteins in terms of their role in protecting peptides/proteins in the stomach and 
intestines, and the potential loss of the peptide/protein to TCII in the blood stream needs 
to be done. 
 One of the major barriers facing oral drug delivery of peptides and proteins is the 
acidic/proteolytic environment of the GIT.1  Previous reports have discussed the inability 
of the transport proteins in aiding in the protection of peptides/proteins from these 
elements.1 The previous authors, however, had no data to support such claims and our in 
vivo work with B12-insulin suggests there is a protecting effect from the transport 
proteins.2  In situ experimentation with the HC-B12 peptide/protein complex or IF-B12 
peptide/protein complex in the presence of simulated stomach and intestinal conditions 
would help to establish this important ability of the transport proteins.  The production of 
simulated stomach and intestinal conditions has been well established and can be 
followed from literature.3   
Knowledge of whether there is loss of insulin activity through TCII-B12 based 
binding to the TCII receptor CD320, as opposed to the desired binding to the insulin 
receptor CD220 (see Figure 58), needs to be investigated.  If, upon oral delivery to the 
circulatory system, a significant proportion of the conjugate binds to the CD320 and the 
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rest goes to the target CD220, then modification of the conjugate to minimize CD320 
binding would immediately improve the response of the oral B12-insulin conjugate and 
ensure an optimal system had been obtained. 
 
Figure 58. Rendering of B12-insulin (yellow-blue) bound by TCII (red and dark blue) 
produced by collaborator Dr. Damien Allis at Syracuse University. It is possible for such 
a structure to bind either the TCII receptor CD320 or the insulin receptor CD220 as 
indicated. The image was altered from 
2
 with permission of The Royal Society of 
Chemistry (RSC) on behalf of the Centre National de la Recherche Scientifique (CNRS).  
 
The effect of different B12 modifications on the binding affinity of the three 
transport proteins has been extensively documented,4-6 with studies showing conversion 
of the b propionamide group into a carboxylic acid (see Figure 59) reducing binding of 
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B12 by human TCII.
6-8  To investigate the binding of TCII, a B12 b carboxylic acid based 
insulin conjugate( B12 b acid-insulin) was synthesized with the intent of comparing its 
activity to that of previously reported, orally active B12-insulin in a rat model.  
Recognition by IF is not completely removed for such a modification, making the B12 b 
acid-insulin an intriguing and worthwhile study of CD320 vs. CD220, since if positive 
results were obtained, the final conjugate could still be used in oral form.6 
 
Figure 59.  Structure of B12 with side chain propionamides indicated.  Conversion of the 
propionamide at the b position to a carboxylic acid is cited as reducing TCII protein 
binding of B12.
7, 8 
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 Previous reports of the synthesis and purification of the b monocarboxylic acid 
show it is a very time consuming processes.7, 9-11  By utilizing a microwave reactor, the b 
monocarboxylic acid was synthesized in the Doyle lab in three min.  Subsequently a one-
step RP-HPLC purification method was established using a C8 column with a step 
gradient of 2% B for 3 min, 10% B 3.1 to 8 min, 15% B 8.1-13.0 min and 20-80% B 13.1 
to 20 min with A: H2O and B: MeOH (See Figure 60).  The difficulty with purification is 
a result of the number of byproducts in the reaction.  Carboxylic acid formation can occur 
at one (mono), two (di), or three (tri) propionamide positions (b, d, or e).  The 
tricarboxylic acid elute first, followed by the dicarboxylic acids and the individual 
monocarboxylic acid.  B12 fragments are also byproducts which elute from Tr 15-31 min. 
The peak at 13 minutes corresponds to the b monocarboxylic acids as determined by 
literature comparison and 1D and 2D NMR.  
 
Figure 60.  RP-HPLC of B12 b carboxylic acid derivative. 
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 The ability of TCII to bind our synthesized b-carboxylic acid derivative was 
explored by collaborators at Arrhus University in Denmark.  The Nexo group had 
recently demonstrated that the B12 transport proteins are species specific and that some 
species have only two transport proteins (IF and TCII) with altered TCII binding 
properties.  Experimentation with human and mouse TCII established the b 
monocarboxylic acid derivative had reduced binding with human TCII, as literature 
would suggest, but was still bound by mouse TCII.  Furthermore, the binding studies with 
the B12 b carboxylic acid-insulin conjugate (AKP2 in Figure 61) vs. the B12-insulin 
conjugate (AKP1 in Figure 61) were shown to bind at comparable levels in mouse and 
human TCII.  This result was very interesting and suggested an interaction between 
insulin and TCII that negated the ability of TCII to bind the b carboxylic acid, which 
should be further studied.  These studies also demonstrated the need to evaluate the 
animal model used for further exploration into the potential loss of protein/peptide to 
TCII binding.   
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Figure 61.  Competitive binding study of human TCII vs. mouse TCII with B12-Insulin 
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(AKP1), B12 b carboxylic acid-insulin (AKP2), B12 b carboxylic acid (Acid) and control 
B12 from two sources (B12 USA and B12 DK).    
6.2 Glucagon-like Peptide-1 
 The next step for the B12-GLP-1 conjugate will be to assess its in vivo 
bioavailability and uptake upon oral administration.  Bioavailability will be assessed 
through food intake and body weight gain following subcutaneous injection in male 
Sprague dawley rats (SD).  The uptake and bioavailability of orally administered B12-
GLP-1 will be determined in an obese diabetic model, Zucker diabetic fatty (fa/fa) rats 
(ZDF).  In these experiments, bioavailability of the conjugate will be assessed by: 
changes in food intake and weight gain relative to baseline and controls; and amelioration 
of the rodent’s insulin response to glucose stimulation as compared to GLP-1 and vehicle 
treated controls.   
 The therapeutic use of GLP-1 is limited by a short half-life (1-2 min), due 
primarily to degradation by the enzyme DPP-IV.12  Exendin-4 (Ex-4) is a DPP-IV 
resistant GLP-1 agonist currently approved for the treatment of T2D (as exenatide, brand 
name Byetta).13  A drawback of Ex-4 based therapy is that, as a peptide, it needs to be 
administered subcutaneously (s.c).1  An orally active Ex-4 may offer advantages in areas 
of patient acceptance/adherence to a regimen.14  Since native GLP-1 is secreted by the 
intestinal L cells, an orally delivered GLP-1 agonist would also have the highly 
significant possibility of mimicking the natural physiological effects of native GLP-1 
more closely, in particular by interacting with the vagal afferent fibers of the 
gastrointestinal (GIT) tract (not affected by the s.c administered form).15, 16  
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 A B12-exendin-4 conjugate would be synthesized using CDT coupling chemistry 
between the B12 ribose 5’-hydroxyl group and lysine K12 residue of Ex-4.  No significant 
reduction in peptide activity has been shown when conjugation occurs at K12 of Ex-4.17 
Ex-4 will be purchased with FMOC protection at the N-terminus to aid in selective 
conjugation and the FMOC protection will be removed prior to biological testing.  
Purification will be achieved by RP HPLC using a C18 column. B12-exendin-4 will be 
characterized by electronic absorption and circular dichroism (CD) spectroscopy, 
MALDI-ToF mass spectrometry and B12 binding studies with IF and TCII.  These 
experiments will produce data confirming the conjugate is pure, coupled correctly, has 
remained folded through the chemical coupling procedure and the B12 is still recognized 
by the transport proteins needed for oral delivery. To confirm the biological function of 
B12-exendin-4 and to gauge the effects of B12 conjugation on Ex-4, in vitro bioassays 
(CRE-luciferase in HEK 293-GLP-1R cells, insulin secretion in human islets monitored 
by ELISA, and Ca
2+
 stimulation in HEK293-GLP1R cells) will be performed, as for B12-
GLP-1 previously investigated (see Chapter 3). 
6.3 C-peptide 
 The B12 uptake pathway is not without its pitfalls.
1  The limitations of the B12 
uptake pathway are known and include a limited uptake capacity.  Therefore, the oral 
delivery pathway of B12 may be better suited for a non life threatening peptide, such as C-
peptide, which requires very little to produce a desired effect.  Recent studies have shown 
the health benefits of C-peptide replacement therapy in patients with type I DM.18  
Recombinant protein expression of a C-peptide mutant will allow for conjugation to B12.  
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An attempt to orally delivery C-peptide could be a great step forward in the treatment of 
complications associated with diabetes.  
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Vitamin B12 in drug delivery:
breaking through the barriers to a
B12 bioconjugate pharmaceutical
Susan M Clardy, Damian G Allis, Timothy J Fairchild & Robert P Doyle†
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Importance of the field: Vitamin B12 (B12) is a rare and vital micronutrient for
which mammals have developed a complex and highly efficient dietary
uptake system. This uptake pathway consists of a series of proteins and
receptors, and has been utilized to deliver several bioactive and/or imaging
molecules from 99mTc to insulin.
Areas covered in this review: The current field of B12-based drug delivery is
reviewed, including recent highlights surrounding the very pathway itself.
What the reader will gain: Despite over 30 years of work, no B12-based drug
delivery conjugate has reached the market-place, hampered by issues such
as limited uptake capacity, gastrointestinal degradation of the conjugate or
high background uptake by healthy tissues. Variability in dose response
among individuals, especially across ageing populations and slow oral uptake
(several hours), has also slowed development and interest.
Take home message: This review is intended to stress again the great poten-
tial, as yet not fully realized, for B12-based therapeutics, tumor imaging and
oral drug delivery. This review discusses recent reports that demonstrate
that the issues noted above can be overcome and need not be seen as
negating the great potential of B12 in the drug delivery field.
Keywords: B12, cobalamin, haptocorrin, intrinsic factor, peptides, transcobalamin
Expert Opin. Drug Deliv. [Early Online]
1. Introduction
The consumption of vitamin B12 (B12; cobalamin) is essential for the survival of all
living cells. B12 is produced naturally by bacteria and all other species must acquire
the vitamin through their diet. There are two major biologically active forms of B12:
methylocobalamin and adenosylcobalamin. Methionine synthase uses methylocoba-
lamin to produce the amino acid methionine from homocysteine, and
methylmalonyl-CoA mutase uses adenosylcobalamin as a cofactor to produce succi-
nyl CoA, an important molecule in the TCA cycle [1]. Mammals have developed a
complex uptake pathway for B12 involving a series of transport proteins [1-3]. For the
purposes of this review, the uptake pathway is discussed only superficially. For a
more in-depth discussion of the transport proteins, the reader is referred to recent
reviews by Banerjee et al. [1] and Randaccio et al. [4].
B12 is a water-soluble vitamin (molar mass 1355.38 g/mol as cyanocobalamin)
with a highly complex structure, comprising a midplanar corrin ring composed of
four pyrroline elements linked to a central cobalt(III) atom (see Figure 2 later).
The corrin ring is similar to the more commonly known porphyrin structure but
with key differences. Corrin rings have a greater degree of saturation compared
with porphyrins and the increased number of sp3 carbons confers greater flexibility
to the corrin. In addition, there is greater asymmetry to the corrin ring, the latter the
result of a 15-carbon ring over the porphyrin 16-carbon structure [1].
10.1517/17425247.2011.539200 © 2011 Informa UK, Ltd. ISSN 1742-5247 1
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Several functional groups are readily available for modifica-
tion on B12. Only a few modification sites, however, maintain
the recognition needed to utilize the full B12 uptake pathway
necessary for oral delivery (see Figure 1). Other modifications
can be used to target specific proteins while reducing
affinity for others, a fact recently exploited to target hapto-
corrin (HC)-positive tumors [5]. An in-depth discussion of
modification sites can be found in Section 2.
B12 is initially released from food by the action of peptic
enzymes and the acidic environment of the gastrointestinal
system [6]. It is then bound and transported by two glycopro-
teins, HC and intrinsic factor (IF) [2]. Haptocorrin is secreted
by salivary glands and released also by the gastric mucosa.
Haptocorrin has a high affinity for B12 under acidic condi-
tions (pH < 3) and so protects B12 from acid hydrolysis.
The HC:B12 complex travels from the stomach to the duode-
num, where the increased pH (> 5) decreases the affinity of
HC for B12 [7]. Haptocorrin is also enzymatically digested
here. On release from HC, B12 binds to the second of the
two gastric transport glycoproteins, IF.
Intrinsic factor is a 43.4 kDa glycosylated protein that is
secreted from the gastric mucosa and the pancreas [2]. The
IF protein facilitates transport across the intestinal enterocyte,
which occurs by receptor-mediated endocytosis at the apically
expressed IF--B12 receptor (cubilin) [8]. Cubilin works to
transport B12 in concert with an anchoring protein amnion-
less (Am) [6]. Following transcytosis, and between 2.5 and
4 h after initial ingestion, B12 appears in blood plasma bound
to the third trafficking protein, transcobalamin II (TCII) [3].
The holo-TCII is cellularly internalized by the TCII receptor
(TCII-R). B12 is released by the degradation of TCII by lyso-
zyme. Another receptor, megalin (MG), can reabsorb filtered
holo-TCII from primary urine. The TCII-R and megalin
receptors then ensure widespread delivery and maximal use
of B12 [1].
Knowledge of the binding between B12 and its various
transport proteins is critical if the system is to be successfully
translated from bench to bedside. In the last 5 years there has
been an explosion of critical structural data related to the B12
uptake pathway, with the publication of the IF [9], TCII [10]
and cubilin(5--8)-IF-B12 [8] structures. One missing piece in
the B12 puzzle is the crystal structure of HC. Indeed, a real
understanding of the functions of HC remains elusive, with
suggestions it may play a bacteriostatic role in the mouth
and bloodstream [11]. What is true now is that researchers
have a better understanding of how B12 interacts with its
transport proteins, and how these transport proteins interact
with their receptors. The implications this can have on drug
delivery and sites of potential conjugation can then be better
detailed, rationalized and hence optimized.
Along with the wealth of knowledge from the experimental
field is the recent use of modern theoretical approaches to
B12-based drug design. The foundational work for B12 molec-
ular modeling studies has all but been completed with the
publication of several recent papers providing both force field
parameters and charge density information at levels of theory
comparable to, or exceeding, the quality of the force fields
within which the parameters have been used [12-17]. With
very little modification, a family of B12 structures can be
turned into topologies for force field parameter assignments.
This has opened the door to a wider range of B12 molecular
modeling studies, including studies of the periplasmic binding
protein BtuF [16] and the TonB-dependent transporter
BtuB [17]. Computational approaches have shown themselves
to be a powerful interpretive tool for explaining the various
structures involved in B12 transport and providing a useful
tool for rational drug design.
Based on the results of recent years, it is clear there is great
hope for a B12-based bioconjugate to reach the market-
place sooner rather than later. This review details and expands
on the points made in this introduction and discusses the
future of the field.
2. Review of the B12 dietary pathway in drug
delivery
2.1 Modifiable points -- solvent-accessible pocket
The solvent-accessible surface of B12 is critical when consider-
ing B12-based bioconjugates. The key point to be made
upfront is that there is solvent accessibility. For TCII this sol-
vent exposure is ~ 6.5% (~ 80 Å2). For IF this exposure is
twice as high at ~ 13% (~ 163 Å2), with HC the least accessi-
ble at 3.2% (~ 40 Å2) [18]. This exposure allows for select sites
to be utilized when designing a B12 conjugate, for general
pathway acceptance or for selecting specific parts thereof.
B12 and the molecule of interest can be: i) coupled directly
together; ii) held apart by ‘spacer’ units to produce distance
between the B12 and drug; or iii) carriers can be conjugated
to B12 with the desired drug contained, unconjugated, within
this carrier. Several functional groups are readily available for
modification on B12, including propionamides, acetamides,
hydroxyl groups, the cobalt(III) ion and the phosphate moiety.
Only a few modifications are capable of maintaining the
recognition of all three transport proteins needed to utilize
Article highlights.
. An overview is provided of B12 structure, chemistry, and
uptake proteins and receptors.
. An overview is given of the use of the B12 dietary
pathway in drug delivery.
. Methods and highlights in the use of B12 conjugates to
utilize/target specific B12 proteins and
associated receptors.
. In the section on general uses of B12 in drug delivery,
oral delivery is discussed, especially of proteins and
peptides, and general small molecule delivery by oral
and invasive means is discussed.
This box summarizes key points contained in the article.
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the full B12 uptake pathway effectively in an oral manner. This
limitation is a result of the manner by which the B12 is bound
by the transport proteins and a strong indicator even in the
absence of structural information on the similar solvent accessi-
bility of B12 positions on binding in all cases. The size of the
drug is important when considering the location for conjuga-
tion, as are the transport proteins being utilized, because the
three transport proteins are not created equally. Conjugation
of drugs resulting in the recognition of all three transport
proteins has been successful with B12 at four major sites: i) to
the peripheral corrin ring e-propionamide [19]; ii) through the
5¢-hydroxy group of the ribose unit of the a-‘tail’ [20];
iii) through the 2¢-hydroxy group of the ribose unit of the
a-‘tail’ [21]; and iv) to the cobalt cation (see Figure 2) [22].
Examination of the recently published crystal structures of
B12 bound with TCII [10] and IF [9] provides a better under-
standing of why such positions are available for conjugation
without complete loss of recognition. TCII was the first trans-
port protein crystallized [10]. The structure revealed several
important details about points of modification on B12,
including the presence of hydrogen bond formation between
various residues in TCII and B12’s phosphate moiety and
the side chains of the corrin ring. The further stability found
to occur with the replacement of the Co’s axial ligand with a
histidine residue from TCII [10] was also rationalized. How-
ever, this latter substitution is not necessary for the binding
of TCII and will not occur if a stable Co--C bond has been
formed, such as the Co--CN in cyanocobalamin. The crystal
structure [10] and molecular dynamics studies [14] have also
shown that TCII does not completely encompass B12 on
binding, and leaves an exposed section of the vitamin accessi-
ble to solvent. The 1.4 nm solvent-accessible pocket of B12
bound to TCII shows that the phosphate and ribose hydroxyl
groups are left protruding into the solvent, but only the ribose
5¢-hydroxyl tail is open to the environment enough such that
it can easily accommodate the conjugation of large molecules
(see Figure 3). Depending on the size of the conjugate, the
three other sites have been shown to accommodate molecules
without interference with TCII binding. It has been estab-
lished that recognition and uptake of the vitamin still occur
on modification of the b-axial position of the B12’s
cobalt, the a-axial ribose tail and several exterior carboxylic
acid groups (produced by hydrolysis of side-chain
propionamides) [10,19,22].
Proximal
Stomach
IntestineTransport
across ileal
epithelium
CB
Nucleus Nucleus
Nucleus
CB
TCII
TCII
Mouth
HC HC
B12
B12
B12
B12
B12
B12 TCII
TCII-R
Receptor-mediated
endocytosis
MG (extraction from urine)
B12
Dietary source of B12 is
broken down in mouth
releasing B12; bound by HC
Secretion into
blood
IIeal enterocyte
Cell requiring B12
B12 internalized
in cell
ileum
Am Am
IFIF
Figure 1. Uptake pathway for B12 from oral consumption to cellular entry. Although B12 has been cited as a potential carrier
of drugs for several years, there are several limitations, including uptake capacity (~ 2.5 µg/day for an adult human [45]), that
have limited its use in drug delivery so far.
Am: Amnionless; CB: Cubilin receptor; HC: Haptocorrin; IF: Intrinsic factor; MG: Megalin; TCII: Transcobalamin II; TCII-R: Transcobalamin II receptor.
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The crystal structure of IF was published in 2007 [9].
This ~ 60 kDa protein is highly glycosylated and proved dif-
ficult to crystallize. The IF-B12 complex has several similari-
ties to the previously discussed TCII-B12 complex, including
several of the same hydrogen bond formations between the
protein and the vitamin. The IF-B12 complex does not incor-
porate a histidine residue in the b-axial position, however,
and ~ 13% of the B12 is solvent-accessible compared with
only 6.5% of the B12 in the TCII-B12 complex [18]. The
crystal structure revealed a possible mechanism, involving
pH, for the transfer of B12 from IF to TCII, allowing
researchers a better understanding of the last few steps of the
B12 pathway [9].
While attention has concentrated on maintaining the bind-
ing between the transport proteins and B12 bioconjugates, lit-
tle is known about what impact, if any, modifications to the
B12-transport protein complex might have on subsequent
receptor binding. Until recently the structure of a holoprotein
complex bound to a B12 receptor was unknown. In 2010,
Andersen et al. published the structure of cubilin(5--8)-IF-B12
(see Figure 4) [8]. This publication provided an outline of
how the holo-complex interacts with the receptor, allowing
researchers a new tool to determine the implications of
conjugation on receptor binding.
2.2 Targeting specific transport proteins
On delivery to the bloodstream, a B12 conjugate typically will
be acquired by the TCII protein. In cancer therapy/imaging,
the hypothesis in B12-based targeted delivery has historically
been that increased TCII-R expression (as much as 3- to
26-fold in certain patients [6]) in a variety of cancers such as
testis, breast, ovarian, thyroid, uterine, and brain cancer
would provide sufficient selectivity over healthy tissue. This
characteristic of B12 led to the production of both small mol-
ecule organic and inorganic B12 bioconjugates with various
applications in medicinal chemistry. Although the bioconju-
gates are discussed in more detail in the next section, it should
be noted here that the major problem associated with these
bioconjugates has been background uptake by healthy tissue.
In an attempt to overcome background uptake, HC has
been targeted more recently. Cytoplasmic or membrane-
associated HC has been suggested to be de novo expressed [5]
or overexpressed [23] in certain cancer lines. To target HC
over TCII, Waibel et al. disrupted the interactions between
β side
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Figure 2. Structure of vitamin B12. Molecular structure of XCbls: the central cobalt(III) atom is six-coordinated, with the
equatorial positions filled by the nitrogen atoms of the corrin macrocycle. The (conventionally) ‘lower’, ‘a’-axial site is
occupied by an imidazole nitrogen atom from a 5¢,6¢-dimethylbenzimidazole base whereas the ‘upper’, ‘b’-axial site can be
occupied by various X groups (e.g., CN-, CH3
-, Ado-, NO2
-, SCN-, SeCN-, SO3
- and thiourea). The corrin ring incorporates seven
amide side chains, three acetamides (a, c, g) and four propionamides (b, d, e, f). The four pyrrole rings are usually indicated
as A, B, C and D, as shown. Areas lightly shaded in pink have been commonly used for conjugates that maintain HC, IF and TCII
binding. The area shaded in yellow, namely the b-propionamide, has been used, on conversion to the carboxylic acid, for HC-
specific targeting. This HC-specific targeting is important where background TCII-R uptake prevents selectivity of cancerous
tissue over healthy tissue.
Haptocorrin; IF: Intrinsic factor; TCII: Transcobalamin II; TCII-R: Transcobalamin II receptor.
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B12 and TCII by utilizing the b-propionamide site after mod-
ification to the b-monocarboxylic acid (the yellow shading
seen in Figure 2) [5]. This method negates the possibility of
oral uptake but demonstrated greater tumor targeting by
reducing prevalent TCII-based uptake of the conjugates into
healthy cells. This is a considerable breakthrough for B12-
based cancer therapeutics because it demonstrates that one
of the oft-stated problems of using B12 systems, namely non-
specific cell uptake, can be addressed, at least towards cancer
cell lines with de novo HC expression. Images obtained with
single-photon-emission computed tomography (SPECT)
agents targeting HC and TCII are shown in Figure 5.
2.3 General uses of B12 in drug delivery
2.3.1 Increased solubility
The solubility behavior of a drug is one of the key physico-
chemical properties that can determine clinical efficacy and
is often the cause of the failure of a drug to reach the mar-
ket [24]. For orally administered drugs, the compound needs
to be highly soluble or become immersed in the intestinal
fluid to allow for absorption (assuming enterocyte passage is
also feasible). For intravenously administered agents, suffi-
ciently high solubility in the plasma is vital to diminish unde-
sirable precipitation in the systematic circulation. In its native
form, B12 is a highly soluble vitamin [10.2 mg/ml] that can be
used to increase the solubility of compounds that would
otherwise have little ability to be used as a drug.
2.3.2 Oral delivery
Few peptide/protein-based drugs have the ability to survive
the gastrointestinal tract and/or cross the intestinal wall to
make it to the bloodstream. Therefore, delivery of a pharma-
ceutically viable amount of peptide/protein is unachievable
through simple oral dosing. At present, administration of
these compounds is done through subcutaneous injections.
This approach is time-consuming, painful, inconvenient,
and can lead to allergic reactions near the sight of injection,
as well as lower patient compliance. The improved ease of
administration associated with the oral-enteric pathway pro-
vides an attractive means for the delivery of many pharmaceu-
tical drugs because higher patient compliance is likely [25,26].
As a highly soluble, non-toxic vitamin with an extremely
effective uptake pathway, B12 makes for an attractive vehicle
for the oral delivery of drugs [26]. Although great strides have
been taken in the field, the use of the uptake pathway is not
without disadvantages, including a limited oral uptake
capacity (1 -- 2 µg of B12 per day [27]) and the inability to
protect peptides/proteins from proteolytic degradation [28].
However, recent results, both experimental and theoretical,
offer new strategies to overcome these issues, and these are
discussed below.
2.3.3 Delivery of small molecules
For years, B12 has been utilized for the delivery of imaging
agents and therapeutic drugs for the treatment and diagnosis
of rapidly proliferating cells owing to the increased need for
B12 in such cells (see Table 1). Early investigators demon-
strated that cobalt radionuclides (57Co, 58Co, 60Co) could
be used to label B12 for imaging [29-31]. The half-life of the
radionuclides, however, required the dosage for humans to
be too small for successful external images and the radioactive
compounds were shown to accumulate in the liver, pancreas
and kidneys, leading to organ damage [32]. In an attempt to
overcome these issues, some extra radionuclides, including
111In (2.8 days; 0.245 MeV-g) [32], 131I (8 h; 364 keV-g ,
606 keV-b) [33] and 99mTc (6.02 h; 140 keV-g) [34], have
been conjugated to B12 for labeling purposes since these
early days. Unfortunately, these experiments still resulted in
Solvent-accessible 5′ ribose-OH and phosphate positions Cobalt (III) inaccessibility in the TCII-B12 crystal structure
180°
Figure 3. The solvent-accessible pocket of TCII bound to vitamin B12. The left pair of images show the 5¢ ribose and phosphate
positions (cyan) accessible through a 1.4 nm gap in the solvent-accessible surface of TCII (red = a-domain, blue = b-domain,
green = a/b linkage). The images on the right show the inaccessibility of the cobalt(III) coordination position in the crystal
structure (a position at which functionalization has been shown to occur without a deleterious change to binding affinity in a
few instances, indicating a TCII structural change at this position must occur to accommodate the steric bulk of a ligand. See
text and [10]).
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undesired organ accumulation, limiting the amount of
drug delivered to cancerous cells and demonstrating high
background uptake in healthy cells [31-34].
In 2009, Siega et al. determined it was possible to deliver
Gd3+ to cancer cells by conjugation to B12. By using the metal
chelating agent DTPA, a B12--Gd
3+ conjugate was con-
structed. The Gd3+ moiety conjugated to the 5¢ ribose of the
B12 did not affect the binding of the B12 transport proteins.
Viability tests on human myelogenous leukemia K562 cells
incubated with the conjugate showed a significant decrease
in cell viability compared with those incubated with the B12
parent compound and/or the Gd3+ ion alone [35]. Given that
this system utilized conjugation at the 5¢-ribose position,
allowing TCII recognition, it can be postulated that this
system, if tested in vivo, will give poor tumor specificity.
Nitric oxide (NO) has been demonstrated as a potential
candidate for antitumor therapy owing to its ability to cause
both necrosis and apoptosis [36]. In 2002, Bauer et al. set
out to demonstrate that conjugation of NO to B12 would
result in a greater anticellular effect against malignant cells
compared with normal cells. Nitrosylcobalamin (NO--B12)
is a B12 derivative with NO as the b-axial ligand. Once the
conjugate was in the cell NO was detached from B12, causing
inhibition of cellular metabolism and directly damaging
DNA, leading to apoptosis. The antiproliferative efficacy of
the conjugate was determined in 22 human tumor cell lines
and two non-cancer cell lines. It was determined that tumor
cell lines were more sensitive to the conjugate than the normal
cell lines. The conjugate was determined to inhibit tumor
growth in vitro and in vivo by activation of the extrinsic
apoptotic pathway [36].
Colchicine is a highly toxic compound that has been used
as a therapeutic agent for a wide variety of diseases since the
sixteenth century [37]. In recent years, it has been investigated
as a potential anticancer drug. It has a similar mode of action
as taxanes but is far more water-soluble, making it more
accessible to biological applications. Unfortunately, colchi-
cine does not have the ability to distinguish healthy from
cancerous cells and colchicine chemotherapy results in over-
whelming systematic toxicity [37]. In 2004, Grissom and
co-workers used B12 to deliver colchicine to cancerous cells.
To make the B12 conjugate, the colchicine analogue 2
(2-(4-acetylphenoxy)-N-acetophenocolchicine) was synthe-
sized. To make the B12 conjugate, the colchicine analogue
2(2-(4-acetylphenoxy)-N-acetophenocolchicine) was synthe-
sized. Compared with the unmodified colchicine, the ana-
logue retained activity with only a minimal loss of toxicity.
Using an acid labile hydrazone linker, the analogue was
then attached to the b-axial ligand of B12. The linker allowed
for a pH-dependent release of colchicine in acidic condi-
tions. Once taken into the cell by means of the B12 receptors,
colchicine was released to interact with microtubules but
showed a 10-fold decrease in toxicity [38]. As noted before,
this system in vivo would again be predicted to suffer from
TCII-based non-selective uptake/accumulation.
A progression of papers has recently appeared in the use of
B12 to deliver Pt drugs, focusing on cisplatin and analogues
thereof. In this instance it was shown that B12 can act as a
ligand for cisplatin by the formation of a cyanide-
bridged species between the b-axial ligand of B12 and Pt [39].
Alberto and co-workers showed that the B12--cisplatin conju-
gate retains a labile chloride ligand that can be exchanged
with ligands such as guanine, allowing the conjugate to
behave in a similar way to cisplatin [40]. In 2008, Alberto
and co-workers continued their initial work with the cisplatin
derivatives and synthesized several prodrugs around the
{B12-CN-Pt-R} moiety (see Figure 6) [22].
Using an in vitro adenosylation assay from Salmonella
enteric, the group was able to show that Co III was reduced
to Co II and the Pt II complex was released [22]. As the Pt II
complexes were shown to be released, B12-mediated delivery
of Pt complexes showed promise. In 2010, the in vitro
cytotoxicity of the {B12-CN-Pt-R} conjugates was pub-
lished [41]. The preliminary results suggested a lower
activity (IC50 between 8 and 88 µM) than for cisplatin
alone. It is hypothesized that the limited B12 uptake capac-
ity, discussed earlier, is most probably to blame. Studies
on the effects of the uptake capacity on concentration are
underway [41].
Figure 4. Cubilin(5--8)-IF-B12 structure. This structure, pub-
lished in 2010 (see Protein Data Bank accession code 3KQ4),
shows for the first time the interaction between holo-
IF (pink and green) and CUB5--8 domains (blue with calcium
as red spheres). The structure provides a road map to study
B12 conjugates bound to IF to explore the implications of B12
modification on IF binding and subsequent receptor inter-
actions. The structure also offers up potential mutagenesis
sites on IF for use of IF as a delivery agent itself. Neither of
these two latter points has been studied extensively so far.
Image modified with permission from [8].
IF: Intrinsic factor.
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2.3.4 Delivery of peptides/proteins
Table 2 lists the peptide/protein B12 conjugates reported so
far. A comprehensive review of this area has been reported
recently and the reader is referred there [42]. Instead, herein
is discussed the use of molecular dynamics in the development
and understanding of B12-based drug delivery systems using a
B12-insulin conjugate system (see Table 2) as an example of
the power of this approach.
3. Molecular modeling considerations
Molecular modeling serves invaluably in both predictive and
interpretive capacities in modern drug design. The field is lim-
ited in application only by either the availability of proper the-
oretical descriptions of biologically relevant molecules (largely
in the form of molecular force field parameters and topologies,
limitations addressable by parameter generation and validation)
or the absence of experimental data on which to base proper
analyses. For molecular dynamics studies, the limitation is
largely in the form of absent crystallographic or solution-
phase structural information against which to identify struc-
tural candidates and test new designs. As applied to the study
of bioconjugates, the atom-level description of molecular
phenomena afforded synthetic chemists by even modest
computational efforts reveals a great deal about the binding
environment of a molecule. The potential difficulties of designs
based on the placements of steric bulk (that prohibit binding of
the native molecule) or physical inaccessibility of targeted func-
tionalization (that changes the binding of the native molecule)
can be visualized. Insights into possible molecular designs not
readily obvious from either crystallography or macroscale
sample characterization without synthetic efforts that survey
possible candidate positions can also be highlighted.
As a complement tomany of the experimental studies of func-
tionalization positions [43,44], molecular modeling studies reveal
the extent to which the modification potential of the B12 frame-
work itself is greatly limited for new bioconjugate designs by the
nature of its binding within its transport proteins. Using the
binding of B12 to TCII (the complex for which the best struc-
tural information is available [1,3,10]) as a basis for all subsequent
bioconjugate design work (as a disruption at any step in the
transport pathway for B12 is probably deleterious for any biocon-
jugate design), several design considerations were revealed.
These molecular modeling studies provide both a reinforcement
of previous experimental work and insights into approaches for
potential new B12-based delivery designs based on functionaliza-
tion positions deemed accessible, themselves based on the
geometry of the B12--TCII binding interaction.
Tumor
Kidney
Liver
Tumor
Tumor
Bladder
0 100
Thyroid
Thyroid
Intestines
Salivary glands
Lachrymal
glands
A. B.
C. D.
Figure 5. SPECT/CT scans of mice 24 h after intravenous injection of B12-
99mTc conjugates designed to be non-binders to TCII
(HC binder) and binders to TCII. A, C. HC targeting compound. B, D. TCII binding compound. Note increased tumor specificity
obtained with HC targeting. Color scale relates activity.
Reproduced with permission from [5].
HC: Haptocorrin; IF: TCII: Transcobalamin II.
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Any design of B12 bioconjugates must ultimately consider
all of the steps in the B12 transport pathway. In these consid-
erations, it is known that B12 binding to its transport proteins
(HC, IF and TCII) must be conserved. The availability of
partial or complete molecular geometries for TCII [10] and
IF [9] reveals that these two proteins are largely similar in
geometry and binding mode, and indicates that HC is likely
to bind B12 in a similar manner. As the initial computational
study of B12-insulin [44] bioconjugate began with preliminary
experimental results that indicated successful transport (as
determined by cellular glucose uptake), the molecular model-
ing study focused on TCII. As part of any subsequent design
based on B12 delivery, the characterization of the binding
mode of B12 and the flexibility of the a/b domain ‘clamshell’
mechanism of binding by TCII (see Figure 7) produce an ele-
gant picture of one set of readily accessible ‘best-
practice’ approaches for bioconjugate design. This is a very
straightforward model of how adhering to this set of
approaches is likely to produce viable candidates for a wide
variety of delivery targets.
In the previously reported molecular dynamics studies of
TCII with B12 [15], B12-insulin [44] and a B12 bioconjugate
modified with a short peptide tether [14], the simulations
revealed the extent to which the B12 is itself the hydrogen-
bonding glue that binds the TCII into the encapsulation
structure observed in diffraction studies (Figure 7). This
work indicated that the interaction between side chains at
the surface--surface interface between the a- and b-domains
is not a major contributor to the stability of the complex. It
also indicated that TCII in the absence of B12 probably con-
sists of two, poorly interacting fragments linked by a short
tether (obviously the design best suited to binding and pro-
tecting a large biomolecule that cannot easily migrate into
the binding pocket of a less flexible or more inherently
structured protein). As a tool for directing design, the result
of the molecular dynamics simulation showed that modifica-
tions to the B12 are best performed for the generation of
new bioconjugates at positions on the B12 molecule at the
a/b domain interface. Appropriate modifications at this inter-
facial region are not expected to interfere with the individual
B12-a domain and B12-b domain interactions that produce
the encapsulated complex and, further, are made viable
because the ‘clamshell’ design of this complex results in a
a/b breathing motion in the MD simulations that makes
this interfacial region accessible under ambient conditions
and amenable to accommodating small tethering fragments
to couple B12 to some arbitrary molecular beyond the
solvent-accessible surface of TCII (see Figure 8).
The MD simulations provided atom-level explanations for
all of the bioconjugate design work on B12 performed so far.
This study specifically shows why certain chemical modifica-
tions produce viable candidates and some modifications
produce B12 bioconjugates that, by their disruption of the
B12-transport protein binding interaction, do not. Modifica-
tion at the cobalt (Co) is shown to be a reasonable approach
for bioconjugate design because the Co coordination site lies
at the a/b interface and small changes to side chains on the
a-domain reduce steric congestion for coordinated ligands.
This is obvious for small molecules, given the known binding
of B12-CN and B12-CH3. Whereas the cobalt is more embed-
ded than the ribose 5¢-hydroxyl position used as the point of
conjugation in the B12-insulin bioconjugate, the use of a
small, flexible tether that is linked to one molecule and is
Co-coordinated should serve as a reasonable mechanism
for new Co-tether designs, a result supported by previous
experimental work [44].
The MD simulation work also predicts that, owing to the
mechanism of encapsulation and the solvent accessibility of
Pt
C
Co
N N
C
Co
Pt
A. B.
Figure 6. X-ray crystal structures of Pt conjugates of B12. Images were generated from deposited CIF files CCDC-261001 and
CCDC-261002. Both structures display the Co-C-N-Pt ‘core’. Both compounds display micromolar activity but both were less
effective than cisplatin directly, the result, it is hypothesized, of limited B12 uptake [41].
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several regions of B12, the cobalt and ribose 5¢-hydroxyl posi-
tions need not be mutually exclusive as targets for bioconju-
gate design. Instead, with the accessibility of both positions
attributed to the breathing motion of the a/b groups con-
strained largely by their strong binding to the B12 molecule,
the possibility exists for three-component bioconjugates.
This result was hinted at, but was not obvious from, the static
model of the B12--TCII binding interaction in the crystallo-
graphic study. The success of such designs is dependent on
the modes of delivery and the differences in where and
when the degradation of the combined product occurs. This
route does offer a promising path for new work in B12 delivery
approaches that are strongly supported from the synergy of
experimental precedent and supportive computational work.
With the availability of force field parameters and the
reported success of B12 MD simulations in several instances,
one of the few issues in B12 bioconjugate design hampering
continued and more thorough progress is the lack of
structures for proteins within the B12 transport pathway.
Although the success of the B12-insulin bioconjugate
indicates that, even in the presence of a large tethered
molecule, the solvent-accessible binding positions on the
α-Domain CN-B12β-Domain α/β Linkage
180°
90°
Figure 7. The binding of B12 within TCII. Substructures (domains) are differentiated by color. The a- and b-domains at the B12
binding position interact only through hydrogen bonding (and by way of a 10-residue covalent linkage), while numerous
interactions between both domains and the B12 have been characterized experimentally and through previous molecular
dynamics simulations. TCII structure based on [10].
TCII: Transcobalamin II.
Cobalt accessible B12 encapsulation Ribose 5′-hydroxy accessible
30° 30°
Figure 8. The time-averaged structure of B12-TCII from a 50 ns MD simulation. The accessibility of the B12 for chemical
functionalization but potentially limited B12 binding inhibition is shown by way of solvent-accessible surface representations
at both the cobalt (left) and ribose (right) positions.
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B12 are conserved in the members of the transport protein
family, greater subtlety in the modes of chemical modifica-
tion and targeted B12 design will come most easily through
MD simulations that follow a B12 bioconjugate design
through each step in the pathway, for which a modeling
protocol is only as complete as the experimental characteri-
zation of all components. Within even the narrow selection
of B12 modification positions hinted at by the solvent-
accessible crystal structure maps and MD simulations of
the native TCII-B12 complex, a wealth of bioconjugate
design can be envisioned. Completeness in all-computa-
tional approaches to B12 bioconjugate design simply awaits
adequate models of HC and IF, the members of the trans-
port pathway either partially characterized (IF) or still
unavailable (HC).
4. Expert opinion
B12 and the B12 uptake pathway play a fundamental role in
biology and have been explored extensively from a structural
and mechanistic viewpoint. The unique structure of B12 and
the exquisite relationship with its binding proteins have
driven researchers for several decades and continue to this
day to offer up exciting new questions and new avenues of
research. One of these avenues is the use of B12 in drug
delivery, from small molecule in vivo imaging agents to the
oral delivery of large proteins. Inherent restrictions of the
B12 pathway, namely dose limitations and the demand
across cells, healthy or otherwise, for the vitamin, have so
far prevented the realization of a B12 bioconjugate pharma-
ceutical reaching the market. Despite this, several groups are
working to address the challenges of the field, with recent suc-
cesses including HC-specific targeting overcoming TCII
background and the use of polymeric carriers attached to
B12 to increase drug payload.
The future of the field then lies in expanding on these suc-
cesses. The authors envisage building B12 bioconjugates with
multiple payloads, using multiple sites on the B12 molecule
simultaneously. The use of B12 to deliver protein vaccine
components also has great potential. By targeting the immune
response, potentially low doses need be delivered that require
concentrations within the boundaries of the B12 uptake path-
way capacity. The use of the B12 uptake proteins themselves
has also not been explored. Coating a viral particle that
requires an enteric IgA response with HC, for example, may
offer gastrointestinal protection and ultimately provide for
an oral vaccine for such a virus. The very investigation of
the role of HC in blood serum and its structure will also be
a highlight of the coming years in the B12 field. The take
home message of this review is that this is an exciting time
for B12-based drug development, with many of the barriers
thought to be road blocks to successful clinical trials
being overcome.
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The practical use of the vitamin B12 uptake pathway to orally deliver peptides and proteins is much
debated. To understand the full potential of the pathway however, a deeper understanding of the
impact B12 conjugation has on peptides and proteins is needed. We previously reported an orally active
B12 based insulin conjugate attached at LysB29 with hypoglycemic properties in STZ diabetic rats. We
are exploring an alternative attachment for B12 on insulin in an attempt to determine the effect B12 has
on the protein biological activity. We describe herein the synthesis, characterization, and purification of
a new B12–insulin conjugate, which is attached between the B12 ribose hydroxyl group and insulin
PheB1. The hypoglycemic properties resulting from oral administration (gavage) of such a conjugate in
STZ diabetic rats was similar to that noted in a conjugate covalently linked at insulin LysB29,
demonstrating the availability of both positions on insulin for B12 attachment. A possible rationale for
this result is put forward from MD simulations. We also conclude that there is a dose dependent
response that can be observed for B12–insulin conjugates, with doses of conjugate greater than 10
9 M
necessary to observe even low levels of glucose drop.
Introduction
Oral delivery of therapeutic peptides and proteins at clinically
significant and controllable levels is a major challenge in current
medicinal chemistry.1 The oral delivery route aims to open up
new areas of peptide/protein therapeutics associated with the
removal for a need for injection and the concomitant promise of
greater patient quality of life and regimen adherence.2 The major
problems facing oral delivery of peptides/proteins is hydrolysis/
proteolysis in the gastrointestinal tract (GIT) and an inefficient
uptake mechanism for peptides/proteins from the GIT.3 We are
interested in the use of the vitamin B12 (B12) dietary uptake
pathway to address these hurdles and recently demonstrated
clinically relevant plasma concentration of a peptide hormone
(hPYY3-36) achieved through the B12 system in a rat model.
4
B12 is vital for the survival of virtually all living cells. B12 is
synthesized naturally by certain bacteria and all other species
must acquire the vitamin exogenously through diet.5–7 Mammals
have a series of transport proteins in the GIT for the absorption
and cellular uptake of B12.
5–7 The first transport protein, hap-
tocorrin (HC), binds to B12 upon release from food, either in the
mouth or in the stomach and transfers it into the duodenum.8
Once in the intestine, proteases cause the partial degradation of
HC, while a rise in pH promotes the interaction of B12 with
a second transport protein, intrinsic factor (IF). This results in
the transfer of 80% of bound B12 to IF.5 The IF–B12 complex
crosses the ileum via the cubam complex.9 IF digestion occurs
during transcellular passage allowing release of B12 to the serum
transport protein transcobalamin II (TCII).10 TCII is responsible
for cellular entry through the TCblR/CD320 receptor and is
postulated to facilitate blood–brain barrier transport.11
Previously, we reported on the development and character-
ization of an orally active B12–insulin conjugate with hypogly-
cemic properties in the streptozotocin (STZ)-induced diabetic rat
model.12 Results of this work stimulated further study into the
implications of the B12 conjugation on insulin’s ability to bind to
its receptor (INSR/CD220)13 using immune-electron microscopy
and molecular dynamics simulation.14 What is clear from the
results obtained to date is that (i) B12 can aid in delivering insulin
to rat blood serum at levels significantly greater than the
same administered concentration of ‘free’ insulin,12 and (ii) the
B12–insulin conjugate can still dock to CD220 and thus trigger
glucose uptake.13
The use of the B12 pathway to deliver a clinically relevant bolus
of insulin is not possible however, given both the limited uptake
capacity of the pathway and the relatively slow uptake time
for serum delivery (3 to 4 hours) and plasma maximum
(7 hours).15 The possibility of developing an oral, long acting
basal therapy is more feasible, where a low level of long acting
insulin is required and an initial uptake delay is not critical.
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The earlier results with insulin12 and PYY4 have been highly
encouraging and we have become focused on investigating and
improving in vivo residency of B12–insulin conjugates. Before
such an area can be fully explored however, knowledge of (i) the
effects of B12 conjugation on the two main sites suitable for such
on insulin (vide infra) and (ii) dose–response of B12–insulin
conjugates need to be addressed. These important factors are
discussed in this report.
Insulin has two primary sites available for conjugation (the
Na-amino group of phenylalanine B1 (PheB1) and the N3-amino
group of lysine B29 (LysB29)), which allow biological function to
be maintained.16 It is not completely understood which position
is more suitable for modification.16 Significant differences
between both positions upon B12 conjugation would be of great
importance given the limited B12 uptake capacity and the need
therefore to optimize such a conjugate. It is believed that
conjugation at the LysB29 position results in a reduction in
biological activity due to the close proximity to the insulin
receptor binding site.15–18 Therefore, moving B12 further away
from the binding site could result in an increase in biological
activity.15
We describe herein the synthesis, characterization, and puri-
fication of a new B12–insulin conjugate (1), which is attached at
insulin PheB1 (Fig. 1). We hypothesized that 1 may result in an
increase in insulin’s biological activity, while maintaining the B12
uptake capabilities due to the position of B12 attachment in
relation to the insulin receptor binding region. Our previously
investigated B12–insulin conjugate (B12 bound to insulin LysB29,
2)12 was used for comparison purposes (along with free insulin
controls). Both 1 and 2 were coupled at the B12–ribose hydroxyl
group through a carbamate linker. Hypoglycemic properties of 1
and 2 were evaluated in vivo in STZ induced diabetic rats.
Molecular dynamics simulation studies were used to help
rationalize the results. We also report dose dependence in STZ
diabetic rats for a B12–insulin conjugate.
Results and discussion
Chemistry
The synthetic procedures for 1 and 2 were identical unless
otherwise noted. Reaction of B12 with 1,1
0-carbonyl-di-(1,2,4-
triazole) furnished an activated ester at the 50-hydroxyl group.
The activated B12 was then added to a slowly stirring solution
of bovine insulin. The site directed B12 conjugation utilizes
the established difference in reactivity of the amino groups
(LysB29 > GlyA1 [ PheB1) of insulin at pH 9.5.17 For 1, the
more reactive LysB29 and GlyA1 were initially protected with
tert-butyloxycarbonyl (BOC) to allow for specific conjugation of
B12 at the unprotected PheB1 residue as previously described by
Kim et al.17 2 was synthesized without need for a protecting
group due to the high level of reactivity of LysB29 under the
reaction conditions chosen.
Both reactions were extracted by ether precipitation and
centrifugation. The products were isolated by analytical reverse-
phase HPLC. Purification proved challenging due to the simi-
larity in hydrophobicity of unconjugated insulin and B12 conju-
gated insulin. For 1, the BOC protection was adequate to
produce a separation between B12 conjugated and free insulin
(see Fig. S2†). For 2, addition of an excess of FMOC-OSu was
used to aid in purification. The FMOC moiety increases the
retention time of the unconjugated (hence, unprotected) insulin
allowing for separation (Fig. 2). Following HPLC purification,
the protecting groups (BOC or FMOC) were removed with TFA
(1) or piperidine (2) and dialysed against 5 L of H2O overnight in
7000 MWCO dialysis tubing.
The exact site of conjugation was verified by matrix assisted
laser desorption ionization time of flight (MALDI-ToF) mass
spectrometry (MS) analysis of reduced and digested fragments of
1 and 2. The conjugates were first treated with dithiothreitol to
reduce the interchain disulfide bonds linking the A- and B-chain.
MS analysis of the reduced conjugates displayed m/z values
of 2339.0 and 4755.4 corresponding to unmodified A-chain and
B-chain bond to B12, respectively (Fig. 3).
To verify the specific B-chain site, reduced conjugates were
treated with trypsin, which cleaves peptides at the carbonyl side
of arginine or lysine, except when followed by a proline. Reduced
and digested 1 displayed a m/z of 3844.9 corresponding to B1–
B22 plus B12 indicating conjugation at the B1 site (Fig. 3). While,
reduced and digested 2 displayed a m/z of 2286.0 corresponding
to B23–B30 plus B12, indicating attachment at the B29 site
(see Fig. S2†).
Fig. 1 Molecular dynamic stimulation snapshot of TCII (red¼A-chain,
dark blue ¼ B-chain, green ¼ unstructured linkage) bound to 1 [B12
(yellow with light blue Co(III)) conjugated to the first amino acid (PheB1)
on the insulin B-chain (also yellow)].
Fig. 2 The RP-HPLC spectra of an FMOC protected insulin plus B12
reaction monitored at 360 nm (dash) indicating B12 is present and 254 nm
(solid) indicating insulin is present.
Med. Chem. Commun. This journal is ª The Royal Society of Chemistry 2012
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In vivo testing and molecular dynamics (MD)
Comparison between both conjugates was assessed by measuring
blood glucose concentration following oral delivery of 1 and 2
(Fig. 4). Area under the curve (AUC) transformation showed
a significant difference (p ¼ 0.03) between 1 and free insulin
control, consistent with that observed in our earlier report.12
Of interest here is that no significant difference in glucose drop
(p ¼ 0.53) was observed between 1 and 2. Both produced similar
and greater drops over free insulin of the same orally adminis-
tered concentration. This data differs from previous litera-
ture15–18 that demonstrated conjugation position alters the
biological activity of insulin and was not what we expected. We
believe our findings may be explained by components of the B12
uptake pathway, making this result not in conflict with these
earlier findings but rather suggesting a unique result tied to the
use of B12 in insulin conjugation.
To help explain this result we conducted MD simulations on
the binding of 1 with the B12 transport protein TCII. Previous
MD simulations of 2 interacting with TCII13,14 indicated that the
lysine side chain alone provided an adequate tether length to
place the unstructured insulin B-chain region (residues B20–B30)
beyond the steric congestion of the B12 bound TCII structure.
Furthermore, the B20–B30 tail provides considerable length
for placing the most structured region of the insulin molecule
(the complete A-chain and B7–B19 B-chain region) far from the
a- and b-Domains of TCII, thereby not impacting the binding
geometry of the B12 in its internal TCII pocket or the interaction
of insulin with the insulin receptor.13
Formation of 1 does place the B12 several residues from this
structured insulin region, but the effective separation of the
structured insulin region from the TCII binding area is not
obvious from the components themselves given (i) the inability to
predict insulin unfolding of the B1–B7 region (the residues prior
to the first disulfide linkage to the A-chain) to accommodate the
B12 binding within its pocket and (ii) the inability to predict if the
phenylalanine side chain itself would serve as a source of steric
congestion to disrupt B12 binding in its pocket (in 2, the lysine
side chain is itself the tether region between B12 and insulin).
Given the structural similarities between the B12 transport
proteins TCII and IF (and presumed structural similarities
between both and haptocorrin),19 the TCII simulations serve
generally as a guide for predicting how the entire family of B12
transport proteins might behave upon B12 conjugation, at least
when tethered at the B12 ribose hydroxyl group. Insights into the
nature of the B12–insulin/TCII interaction upon PheB1 conju-
gation come from a 15 ns simulation of 1 interacting with the
TCII complex. A representative of the geometry of 1 during these
simulations is shown and labeled in Fig. 5.
The unstructured B20–B30 region of the insulin B-chain was
removed from such calculations. This unstructured loop points
away from the TCII when the B12 is linked at the B1 position
Fig. 3 MALDI-ToF MS spectrum of DTT reduced 1 shows mass at
4754.5 m/z representing B12 attached to the B-chain of insulin. Reduced
and tryptically digested 1 (inset) produces a 3844.9 m/z fragmenting
consistent with B12 attached at the N-terminus of the B strand, as
expected with PheB1 conjugation. The addition of B12 to the B29 position
would produce a 2286.0 m/z fragment, absent in the spectra of 1. Also
absent is B12 attached to the A strand.
Fig. 4 Relative (% pre-gavage) blood glucose concentration following
administration of free insulin (n ¼ 4), 1 (n ¼ 6) and 2 (n ¼ 6).
Fig. 5 A representative structure of 1 as bound within TCII. Significant
residues identified in the text are labeled, including one persistent
hydrogen bond between insulin B-chain residues B4 and B13 in the MD
simulation.
This journal is ª The Royal Society of Chemistry 2012 Med. Chem. Commun.
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requiring a considerable extension of the solvent box, which adds
to total atom count without providing useful information about
the TCII interactions with 1. The representative geometry in
Fig. 6 shows that the PheB1–CysB7 (B1–B7) region of the
B-chain is unfolded from its unmodified, native a-helix geom-
etry. In the snapshot shown, the disruption of a-helical structure
extends slightly past the disulfide linkage (CysB7). This unfold-
ing of the a-helix enables several local hydrogen-bonding inter-
actions to form transiently throughout the 15 ns simulation. One
of the more persistent interactions is the newly formed hydrogen
bond between B4 and B13 (Fig. 5). The result of this unfolding is
that the B1–B7 residues become the long tether that separates the
insulin core from TCII upon binding of the B12–insulin conju-
gate. This tether originates from an otherwise stable a-helix and
is slightly longer than half of the length of the B20–B30 tether in
the previous study. The retention of the B12 within its binding
pocket with no observable deformation of this pocket indicates
that the B1–B7 tether is long enough to separate the two larger
fragments. As an MD simulation of the B12–insulin molecule
already bound in TCII, this simulation indicates only that, once
bound, there are no expected steric issues preventing retention of
the B12 in its binding pocket. Given the clamshell-like binding
mechanism proposed for the B12–TCII complex, it is presumed
that the B12 can bind with at least one domain of TCII first with
the insulin bound, after which the insulin B1–B7 unfolding is
a subsequent step in the enclosure of the complete B12 by TCII.
The 5.0 ns timesteps shown in Fig. 6 (shown without the TCII for
clarity) reveals the extent to which the PheB1–CysB7 is
completely uncoiled upon stable B12 binding in the TCII pocket.
It is this uncoiling induced upon binding by B12 uptake proteins
that possibly explains why both sites on insulin ultimately equate
in function and why such differences were not observed before.
Fig. 6 also reveals the extent to which this uncoiling in 1 is
extended into GlyB8–LeuB11, leaving only ValB12–CysB19 to
retain any preserved a-helical structure despite the reasonably
well-conserved overall structure of the conjugate. Looking then
at the 15 ns simulation, shown in 5 ns snapshots in Fig. 7, the
largest variation in local geometry is not observed at the B12 or
even the B12–insulin conjugate. Instead, the largest variation is
found in the unstructured loops of the a-Domain of TCII,
a result identical to that found in the previous B12–insulin
conjugate simulation study.13 This difference is most
clearly highlighted by comparing the simulation RMSDs of the
a-Domain with both these loops included (Fig. 8, dark red) and
excluded from the RMSD calculation (Fig. 8, light red). In the
case of the loop-excluded analysis, the hexagonal a-helix
framework of the a-Domain (the region responsible for forming
the cleft into which the B12 binds) shows very little change
through the simulation.
We then explored whether a dose-dependent response could be
observed for this pathway with a suitable B12–insulin conjugate.
Dose dependent effects of 1 on blood glucose were assessed in
Fig. 6 5.0 ns snapshots of the 1 along the B-chain a-helix axis (V1) and
perpendicular to the a-helix axis (V2), with both views showing the
gradual uncoiling of the B-chain (PheB1 through LeuB11) over the
course of the simulation. Light blue ¼ insulin A-chain; yellow ¼ insulin
B-chain and B12. The TCII protein is not shown for clarity.
Fig. 7 5.0 ns snapshots of the PheB1-linked B12–insulin/TCII complex.
Light blue ¼ insulin A-chain; yellow ¼ insulin B-chain and CN–Cbl;
red ¼ TCII a-Domain; green ¼ TCII a-/b-Domain linker; dark blue ¼
TCII b-Domain.
Fig. 8 Backbone RMSD plots for the PheB1-linked B12–insulin/TCII
complex. The removal of the a-Domain a-helix-linking unstructured
loops in the TCII a-Domain RMSD analysis (light red) reveals the
persistence of the a-Domain B12 binding region compared to the overall
a-Domain RMSD analysis (dark red).
Med. Chem. Commun. This journal is ª The Royal Society of Chemistry 2012
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STZ-rats and the results are shown in Fig. 9. 1 was administered
at concentrations of 109 M (n ¼ 3), 107 M (n ¼ 3) and 105 M
(n ¼ 2). AUC was calculated for each dose as 1387  297, 795 
202 and 125  15 mmol L1 240 min below pre-gavage blood
glucose concentration for 109 M, 107 M and 105 M doses
respectively. AUC of raw data identified a significant difference
between 109 M and 105 M conditions, but there were no
significant differences between the other concentrations. The
data presented in Fig. 9 demonstrates the ability of the conjugate
to produce a dose dependent reduction in blood glucose. An
increase in concentration from 109 M to 105 M resulted in an
increase of 10–20% drop in blood glucose.
We report herein on the synthesis, purification and charac-
terization of a new B12 insulin conjugate attached at the insulin
PheB1 position. The hypoglycemic properties resulting from oral
administration (gavage) of such a conjugate in STZ diabetic rats
was similar to that noted in a B12–insulin conjugate covalently
linked at the insulin LysB29 residue,12 demonstrating the avail-
ability of both positions of insulin for, at least, B12 attachment. A
possible rationale for this result is put forward from MD simu-
lations, which suggest there is forced un-coiling of the insulin
molecule at either the N- or C-terminal B strand insulin regions,
depending on B12 conjugation site, upon B12 binding protein
interaction with 1 or 2. We also conclude that there is a dose
dependent response that can be observed for B12–insulin conju-
gates with doses of conjugate greater than 109 M necessary to
observe a drop in glucose. In our earlier report on the oral
activity of 2 we demonstrated that the blood glucose reduction
could be blocked by the addition of a large excess of free B12.
However, the administered amount of conjugate (100 nM) was in
great excess of the expected B12 uptake capacity of the rat
(100 nmole per dose),3 signifying an alternative and/or additional
mechanism for the response. Given the confirmed presence of an
insulin receptor (IR) in the intestine of several mammals20,21
including rat22,23 and human,24 it may be that there is an alternate
receptor at play in the uptake of B12–insulin. While the intestinal
IR was not the intended target for our conjugates it is possible
that the conjugation of B12 has resulted in a predominantly
monomeric insulin (necessary for IR binding) capable of inter-
acting with the intestinal insulin receptor, as suggested by
Russell-Jones3. It is also possible that B12 conjugation is greatly
improving insulin stability, presumably as IF–B12–insulin
formed in situ. This hypothesis is consistent with the observed
glucose drop along with observed dose-dependent response.
Under this latter scenario, the blocking of uptake by a large
excess of B12 (>10
5 M) as observed in our earlier work12 would
still be attributed to loss of IF binding, but rather than loss of
cubam mediated uptake, the effect of such loss would be reduced
gastric protection.
If such a route to oral insulin through the insulin receptor is
made available by B12 conjugation it would be a paradigm shift
in our view of exploiting the B12 uptake pathway for oral protein
delivery.
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LETTER ▌A
letterSite-Selective Oxidation of Vitamin B12 Using 2-Iodoxybenzoic Acid 
Site-Selective Oxidation of Vitamin B12Susan Clardy-James, Jaime L. Bernstein, Deborah J. Kerwood, Robert P. Doyle*
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Abstract: Reaction of vitamin B12 (B12) with excess 2-iodoxyben-
zoic acid and 2-hydroxypyridine leads to selective oxidation of the
5′-hydroxyl group of the ribose tail of B12 in a 30% isolated yield.
The acid derivative was purified in one step by HPLC chroma-
tography and characterized by MALDI-TOF mass spectrometry,
1H NMR and 2D (HSQC and HMBC) NMR. The new carboxylic
acid derivative is perfectly suited to make stable amide-based B12
bioconjugates. 
Key words: vitamins, oxidation, 2-iodoxybenzoic acid, carboxylic
acids, cobalamin
Interest in using vitamin B12 (B12) for the oral delivery of
peptides and proteins1 has encouraged us to further ex-
plore the available conjugate sites of B12. Modifications of
B12 that allow for more facile, higher yielding or stable
bioconjugate formation with continued recognition by B12
dietary uptake and transport proteins have been explored
by numerous groups.2–4 Several functional groups are
available on B12 for conjugation, including the 5′-hydrox-
yl group of the ribose tail, the cobalt(III) ion, the phos-
phate moiety, and suitably modified propionamides off
the corrin ring.5 All such modifications suffer from issues
including reduced or complete loss of interaction with one
or more of the B12 binding proteins, stability issues that re-
sult from the production of ester or carbamate bonds, low
yielding conjugation reaction due to the nature of the
functional group, or require problematic purification of
the modified B12 for subsequent conjugation.
2–4 These
limitations have been well investigated6 and a review of
such sites has been reported,7 however, in brief for pur-
poses of perspective for the work described herein: Con-
jugation resulting in the recognition of all three transport
proteins has been most successful with B12 at two major
sites: (i) the peripheral corrin ring e-propionamide, and
(ii) the 5′-hydroxyl group of the ribose unit of the a-‘tail’.
The side chain e-carboxylic acid derivative (Figure 1) al-
lows for a variety of modifications,8 but the synthesis of
the derivative is low yielding and requires laborious puri-
fication, the result, in part, of the formation of b- and d-
carboxylic acid isomers in addition to the desired e-iso-
mer.9 The 5′-hydroxyl group has been cited as being a
more versatile site according to structure–activity rela-
tionships, however, the conjugates have typically been
synthesized as mentioned above, through carbamate or es-
ter bonds. 
Figure 1  Potential sites available for carboxylic acid formation that
also maintain, at least in part, B12 uptake protein recognition and bind-
ing are indicated in red. The atom numbering scheme used for NMR
discussion is also indicated 
The goal of this work was to create a simple route for the
production of a 5′-carboxylic acid derivative of B12 with
facile purification to ultimately produce stable amide-
linked bioconjugates at this optimal position for conjuga-
tion, especially in regard to intrinsic factor binding (criti-
cal for oral uptake of B12 bioconjugates).
10 Herein, we
report the use of the hypervalent iodine reagent, 2-iodoxy-
benzoic acid (IBX) for the selective oxidation of the
5′-hydroxyl group of B12 to the corresponding carboxylic
acid. This is the first time IBX has been utilized for the ox-
idation of such a molecule as B12 and expands the range of
use of this environmentally friendly oxidizing agent.11 
The B12 derivative was synthesized through a modifica-
tion of the method developed by Giannis et al., which in-
corporates the addition of an O-nucleophile to aid IBX in
the transformation of a primary alcohol into a carboxylic
acid (Scheme 1).12 The use of N-hydroxysuccinimide
(NHS) was initially attempted but resulted in the forma-
tion of a product mixture from which it was not possible
to isolate the carboxylic acid, likely due to the formation
of the activated NHS ester, which has been reported as a
dominating product of this reaction.12 Therefore, 2-hydroxy-
pyridine (HYP) was used as the O-nucleophile. To opti-
mize the reaction conditions, a series of experiments were
performed in which the co-oxidant, temperature, and time
were varied (Table 1). The best result was obtained in the
SYNLETT 2012, 23, 000A–000D
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presence of 2.6 equivalents of IBX and 5 equivalents of
HYP in dimethyl sulfoxide (DMSO) at 60 °C.
Scheme 1  Purposed mechanism for the formation of the 5′-carbox-
ylic derivative utilizing IBX and HYP
These conditions resulted in the oxidation of B12 to the
5′-carboxylic acid derivative B12CA in two hours with a
30% yield (see the Supporting Information). It was deter-
mined that a 30% yield was optimal for the IBX reaction
in this case. An increase in temperature, IBX/HYP ratios,
or time resulted in an increase in the amount of byproducts
and/or decomposition of the B12 (especially at tempera-
tures in excess of 60 °C), reducing the yield and compli-
cating purification. The 30% yield is approximately three
times that previously reported for the preparation of the e-
carboxylic acid derivative, with far easier separation (see
below).9 
The crude reaction mixture was precipitated from DMSO
by ether addition and the precipitate was redissolved in
water prior to purification by ion exchange chromato-
graphy using a SAX column. After a 5 minute hold at
100% water, a gradient from 100% water to 35% MeCN–
phosphate buffer (pH 2; 50:50 v/v) over 5 minutes was
necessary for the separation and elution of B12CA (Figure
2). Slight increases in pH above pH 2 resulted in a reduc-
tion in the amount of pure isolated product. HPLC purifi-
cation allowed the recovery and reuse of B12 starting
material, albeit with the oxidized 5′-aldehyde also present
(Figure 2). B12CA was identified as the peak at 13.6 min-
utes retention time. The purity of B12CA was at least 95%,
as assayed by RP-HPLC. MALDI-TOF mass spectrome-
try analysis of B12CA revealed the anticipated molecular
ion peak (m/z = 1343.5 [M – CN]+; Figure 3). 
Figure 2  The RP-HPLC spectra of 5′-carboxylic acid
(tR = 13.6 min) monitored at 360 nm. Unreacted B12 and 5′-aldehyde
co-elute at tR = ca. 5 min, as indicated by MALDI-TOF MS (see also
Figure S1 in the Supporting Information)
Electronic absorption spectroscopy (EAS) was used to es-
tablish the oxidation state of the metal center as Co(III),
with no indication of derivation of the axial ligands bound
to the metal center (εCA361 = 27500 M–1cm–1; see Figure 4)
The structure of B12CA was determined on the basis of 
1H
NMR (see Figure S2) and 1H–13C heteronuclear (HSQC
and HMBC) correlations (see Figures S3 and S4). The 1H
NMR spectra of B12CA revealed the loss of two protons
(δH = 3.75 and 3.92 ppm), when compared to the spectrum
of B12 (CNCbl; see Figures S2 and S5). A comparison of
the HSQC of B12 and B12CA indicates the protons that are
absent in B12CA were originally attached to the R5 carbon
(δC = 63.5 ppm; see Figure S6). HMBC was attempted to
further establish the presence of a carbonyl at the R5 po-
sition (see Figure S4), however, it was not possible to as-
sign the R5 carbon from the HMBC spectra because it
Table 1  Optimization of the Reaction Conditions
Entry Co-oxidant Temp (°C) Time (h) Yield (%)
1 None 50 2 17
2 HYP 50 2 23
3 HYP 50 3 26
4 HYP 50 4 28
5 HYP 50 5 22
6 HYP 60 2 30
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showed no connectivities to any of the ribose protons, and
so was assigned by HSQC.13
A simple amine-containing organic molecule, benzyl-
amine, was conjugated to the derivative to help with the
identification of the R5 carbon by NMR analysis. In the
presence of 10 equivalents of ethyl-3-(3-dimethylaminopro-
pyl)-carbodiimide (EDC) and 20 equivalents 1-hydroxy-
benzotriazole (HOBt) in N,N-dimethylformamide (DMF)
with 1% water, the desired conjugate was produced at
40% yield over the first hour (Scheme 2), thus establish-
ing proof-of-concept for the new B12CA.
The conjugate was purified by using the same purification
method established for the carboxylic acid (Figure 5) and
characterized by MALDI mass spectrometry (Figure S7)
as well as 1D (Figure S8) and 2D NMR (Figures S9 and
S10) spectroscopy.
With the addition of the benzylamine, connectivity to the
R5 carbon was established by HMBC (Figure 6). Specifi-
cally, the protons of CA (δH = 4.42 and 4.50 ppm) showed
direct connectivity to the R5 carbon (δC = 173.8 ppm) as
well as to CB (δC = 140.8 ppm) and CC (δC = 131.4 ppm)
of the benzylamine. The complete assignment of B12CA
and B12CABA can be found in Table S1. 
In conclusion, we have developed a convenient site-spe-
cific oxidation of B12 using IBX and HYP. This new car-
boxylic acid derivative is highly suited to the production
Figure 3  MALDI-TOF MS spectrum of HPLC peak at
tR = 13.6 min, indicating B12CA (m/z = 1343.5 [M – CN]
+) with an-
giotensin I (m/z = 1296.5) as an internal reference 
Figure 4  Absorbance spectrum of 5′-carboxylic acid derivative in
35% HPLC mobile phase B 
Scheme 2  Synthesis of 5′-carboxylic acid plus benzylamine
Figure 5  Purification of the conjugate was established by RP-HPLC
using an SAX column with a gradient from 100% water to 35%
MeCN–phosphate buffer pH 2
Figure 6 Analysis of the B12 5′-carboxylic acid benzylamine deriva-
tive by 2D heteronuclear NMR spectroscopy. (A) The atom number-
ing scheme for the benzylamine attached to R5 of B12 by an amide
bond. (B) Signal assignments made from HSQC. (C) Signal assign-
ments made from HMBC (both 1H and 13C assignment for CA were
made on the basis of HSQC analysis)
D
ow
nl
oa
de
d 
by
: S
yr
ac
us
e 
U
ni
ve
rs
ity
 L
ib
ra
ry
. C
op
yr
ig
ht
ed
 m
at
er
ia
l.
D S. Clardy-James et al. LETTER
Synlett 2012, 23, A–D © Georg Thieme Verlag  Stuttgart · New York
of bioavailable amide bound bioconjugates. The one-step
purification is simple and the synthesis results in a 30%
yield within two hours, which is far in excess of any pre-
viously reported B12 carboxylic acid derivative.
9 The re-
sulting derivative has the potential to form high-yielding
conjugates and we believe will be of considerable use in
the field of B12 conjugation. 
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